Heterocyclic compounds and use thereof as type III tyrosine kinase receptor modulators

专利摘要:

公开号:ES2586527T9
申请号:ES12780613.1T
申请日:2012-10-12
公开日:2017-06-19
发明作者:Michael J. Hadd；Michael D. Hocker；Mark W. Holladay；Gang Liu；Martin W. Rowbottom；Shimin Xu
申请人:Ambit Bioscience Corp；
IPC主号:

专利说明:

image 1
image2
image3
image4
image5
image6
5
10
fifteen
twenty
25
30
35
40
Four. Five
fifty
55


"IC50" refers to an amount, concentration or dose of a particular test compound that achieves a 50% inhibition of a maximum response, such as cell growth or proliferation measured by any of the in vitro or cell-based assays described in This memory.
"Oxo" refers to the group = O attached to a carbon atom.
Pharmaceutically acceptable salts include, but are not limited to amine salts, such as, but not limited to N, N'-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N- benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-1'-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris (hydroxymethyl) aminomethane; alkali metal salts, such as, but not limited to lithium, potassium and sodium; alkaline earth metal salts, such as, but not limited to barium, calcium and magnesium; transition metal salts, such as, but not limited to zinc; and other metal salts, such as, but not limited to sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to salts of mineral acids, such as, but not limited to hydrochlorides and sulfates; and salts of organic acids, such as, but not limited to acetates, lactates, malate, tartrates, citrates, ascorbates, succinates, butyrates, valerates, fumarates and organic sulphonates.
As used herein, and unless otherwise indicated, the term "hydrate" means a compound provided herein or a salt thereof, which also includes a stoichiometric or non-stoichiometric amount of force-bound water. non-covalent intermolecular.
As used herein, and unless otherwise indicated, the term "solvate" means a solvate formed from the association of one or more solvent molecules with a compound provided herein. The term "solvate" includes hydrates (eg, monohydrate, dihydrate, trihydrate, tetrahydrate and the like).
As used herein, "substantially pure" means sufficiently homogeneous to appear free of easily detectable impurities determined by conventional analysis methods, such as thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography ( HPLC) and mass spectrometry (MS), used by those skilled in the art to evaluate such purity, or pure enough so that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities of the substance. Methods for purifying the compounds to produce substantially chemically pure compounds are known to those skilled in the art. However, a chemically substantially pure compound may be, a mixture of stereoisomers. In such cases, further purification may increase the specific activity of the compound.
Unless specifically stated otherwise in the specification, it is understood that the substitution may occur in any atom of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group.
Unless specifically stated otherwise, when a compound may take alternative tautomeric, regioisomeric and / or stereoisomeric forms, it is intended that all alternative isomers be encompassed within the scope of the claimed subject matter. For example, when it is described that a compound has one or more tautomeric forms, both tautomers are intended to be encompassed herein.
Therefore, the compounds provided herein may be enantiomerically pure, or be mixtures of stereoisomers or diastereoisomers.
It should be understood that the compounds provided herein may contain chiral centers. Said chiral centers may be of configuration (R) or (S), or they may be a mixture thereof. It should be understood that the chiral centers of the compounds provided herein may undergo epimerization in vivo. As such, one skilled in the art will recognize that the administration of a compound in its form (R) is equivalent, for compounds that undergo epimerization in vivo, to the administration of the compound in its form (S).
The optically active (+) and (-), (R) and (S) or (D) and (L) isomers can be prepared using chiral syntons or chiral reagents, or can be resolved using conventional techniques, such as chromatography on a chiral stationary phase.
As used herein, "isotopic composition" refers to the amount of each isotope present for a given atom, and "natural isotopic composition" refers to the isotopic composition or abundance that occurs naturally for a given atom. Atoms that contain their natural isotopic composition can also be referred to herein as "unenriched" atoms. Unless otherwise specified, the atoms of the compounds cited herein are understood to represent any stable isotope of that atom. For example, unless otherwise indicated, when a position is specifically designated as "H" or "hydrogen," it is understood that the position has hydrogen in its natural isotopic composition.
As used herein, "isotopically enriched" refers to an atom that has an isotopic composition other than the natural isotopic composition of that atom. "Isotopically enriched" may also refer to a compound that contains at least one atom that has a different isotopic composition.
8 5
10
fifteen
twenty
25
30
35
40
Four. Five


of the natural isotopic composition of that atom.
As used herein, "isotopic enrichment" refers to the percentage of incorporation of an amount of a specific isotope into a given atom in a molecule at the site of the natural isotopic abundance of the atom. For example, 1% deuterium enrichment at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Since the natural distribution of deuterium is approximately 0.0156%, enrichment in deuterium at any position in a compound synthesized using unenriched starting materials is approximately 0.0156%. The isotopic enrichment of the compounds provided herein can be determined using conventional analytical methods known to one skilled in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
When the number of any given substituent is not specified (e.g., halogenoalkyl), one or more substituents may be present. For example, "halogenoalkyl" may include one or more same or different halogens.
In the description herein, if there is any discrepancy between a chemical name and chemical structure, it controls the structure.
"Antineoplastic agents" refers to antimetabolites (eg, 5-fluoro-uracil, methotrexate, fludarabine), antimicrotubule agents (eg, vinca alkaloids such as vincristine, vinblastine; taxanes such as paclitaxel, docetaxel) , alkylating agents (eg, cyclophosphamide, melphalan, carmustine, nitrosoureas such as bischloroethylnitrosourea and hydroxyurea), platinum agents (eg cisplatin, carboplatin, oxaliplatin, JM-216 or satraplatin, CI-973), anthracyclines e.g., doxrubicin, daunorubicin), antitumor antibiotics (eg, mitomycin, idarubicin, adriamycin, daunomycin), topoisomerase inhibitors (eg, etoposide, camptothecins), anti-angiogenesis agents (eg Sutent® and Bevacizumab) or any other cytotoxic agents, (estramustine phosphate, prednimustine), hormones or agonists, antagonists, partial agonists or partial hormone antagonists, kinase inhibitors and radiation treatment.
"Anti-inflammatory agents" refer to matrix metalloprotease inhibitors, pro-inflammatory cytokine inhibitors (eg, anti-TNF molecules, soluble TNF receptors, and IL1), non-steroidal anti-inflammatory drugs (NSAIDs) such as inhibitors of prostaglandin synthase (e.g., choline magnesium salicylate, salicylsalicylic acid, COX-1 or COX-2 inhibitors), or glucocorticoid receptor agonists such as corticosteroids, methylprednisone, prednisone or cortisone.
As used herein, abbreviations for any protective groups, amino acids and other compounds are, unless otherwise indicated, in accordance with their common use, recognized abbreviations or the IUPAC-IUB Biochemical Nomenclature Commission (see, Biochem. 1972, 11: 942-944).
B. Compounds
Compounds of formula I are described herein:
image7
or its pharmaceutically acceptable salts, solvates, hydrates, clathrates, individual stereoisomers, stereoisomer mixture or racemic mixture, wherein:
R1 and R2 are each independently selected from hydrogen, deuterium, halogen, hydroxyl and alkoxy, or R1 and R2 together form = O;
R3 is hydrogen or alkyl;
R4 is cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl, where R4 is optionally substituted with one or more, or 1 to 3, or 1, 2 or 3 groups selected from Q1;
each Q1 is independently deuterium, halogen, cyano, oxo, thioxo, alkyl, haloalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -RuORx, -RuORuN ( Ry) (Rz), -RuN (Ry) (Rz), -RuSRx, -RuC (J) Rx, -RuC (J) ORx, -RuC (J) N (Ry) (Rz), -RuS (O) tRw, -RuN (Rx) C (J) Rx, -RuN (Rx) C (J) ORx, -RuN (RxS (O) tRw, = NORd, or -C (= NRy) N (Ry) ORx, where alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with one or more groups Q3, or 1 to 3 groups Q3; each Q3 is independently selected from deuterium, halogen, hydroxyl , alkyl, halogenoalkyl and hydroxyalkyl;
9
image8
5
10
fifteen
twenty
25
30
35
40
Four. Five


halogen, deuterium, oxo, thioxo, hydroxy, alkoxy, alkyl, halogenoalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclyl, heterocyclyl;
J is O, NRx or S;
each t is independently an integer from 0-2;
n is 1 or 2; Y
q is an integer from 0-4,
wherein the compounds are selected such that: i) when W is CH; W1 is C; Z is S; R1 is hydrogen, or hydroxyl and R2 is hydrogen, or R1 and R2 together form = O; Ring A is not pyridine; ii) when W is CH; W1 is N; Z is S; R1 and R2 are hydrogen, then ring A is not pyrrolidine; iii) when W is CH, Z is NH, R1 and R2 together form = O, q is 0, and R4 is pyridinyl, ring A is not phenyl, iv) when W is CH, Z is NH, R1 and R2 together form = O, q is 0, and R4 is phenyl, then ring A is not pyrrolidine, and v) when Z is N, one of R1 and R2 is methyl and the other of R1 and R2 is H, q is 0, and R3 is pyridine, and W1 is N, ring ring A cannot be piperidine, 1,2,3,4-tetrahydroisoquinoline or isoindoline.
Also described herein are compounds of formula I or their pharmaceutically acceptable salts, solvates, hydrates, clathrates, individual stereoisomers, stereoisomers mixture or racemic mixture, wherein:
R1 and R2 are each independently selected from hydrogen, halogen, hydroxyl and alkoxy, or R1 and R2 together form = O;
R3 is hydrogen or alkyl;
R4 is cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl, where R4 is optionally substituted with one or more, or 1 to 3, or 1, 2 or 3 groups selected from Q1;
Each Q1 is independently halogen, cyano, oxo, thioxo, alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocycluoro-Ryu-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-1-C-alkyl-R-alkyl-R-alkyl-R-alkyl-R-alkyl-R-alkyl-R-N-R-alkyl-R-N-R-1-C-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-1-C group (Rz), -RuN (Ry) (Rz), -RuSRx, -RuC (J) Rx, -RuC (J) ORx, -RuC (J) N (Ry) (Rz), -RuS (O) tRw, -RuN (Rx) C (J) Rx, -RuN (Rx) C (J) ORx, -RuN (RxS (O) tRw, = NORd, or -C (= NRy) N (Ry) ORx, where the groups alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl are optionally substituted with one or more groups Q3, or 1 to 3 groups Q3; each Q3 is independently selected from halogen, hydroxyl, alkyl, halogenoalkyl and hydroxyalkyl;
Y is - (CR5R6) q;
R5 and R6 are each independently hydrogen, halogen, alkyl, halogenoalkyl or hydroxyalkyl;
Z is O, S or NR7;
R7 is hydrogen or alkyl;
each W is independently CR8 or N;
R8 is hydrogen or alkyl;
Ring A is aryl or heteroaryl, optionally substituted with 1 to 4 substituents selected from Q2;
W1 is N or C;
W2 is N, NR9a or CR9b;
W3 is N, NR10a or CR10b;
W4 is N, NR11a or CR11b;
R9a, R9b, R10a, R10b, R11a and R11b are selected as follows:
i) R9a, R10a and R11a are each independently hydrogen or alkyl, and R9b, R10b and R11b are each independently hydrogen, oxo, hydroxyl, halogen or alkyl; or
ii) R9a and R10b, R9b and R10b, R9b and R10a, R10b and R11a, R10a and R11b or R10b and R11b together with the atoms to which they are attached form an aryl or heteroaryl ring, optionally substituted with one or more, or from 1 to 3, or
11 5
10
fifteen
twenty
25
30
35
40
Four. Five


1, 2 or 3 groups selected from Q2; and the rest of R9a, R10a and R11a are each independently hydrogen or alkyl; and the rest of R9b, R10b and R11b are each independently hydrogen, halogen or alkyl;
Each Q2 is independently halogen, cyano, oxo, thioxo, alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocycluoro-Ryu-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-alkyl-R-alkyl-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-C-N-R-alkyl-R-N-alkyl-R-N-R 1 -C (Rz), -RuN (Ry) (Rz), -RuSRx, -RuC (J) Rx, -RuC (J) ORx, -RuC (J) N (Ry) (Rz), -RuC (J) N ( Ry) ORx, -RuS (O) tRw, -RuN (Rx) C (J) Rx, -RuN (Rx) C (J) ORx, -RuN (Rx) S (O) tRw or -C (= NRy) N (Ry) ORx, where the alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with one or more Q4 groups; or from 1 to 3 groups Q4, each Q4 is independently selected from halogen, hydroxyl, alkyl, halogenoalkyl and hydroxyalkyl;
Rd is hydrogen or alkyl;
each Ru is independently alkylene or a direct bond;
Rw is alkyl, halogenoalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenyl alkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl;
each Rx is independently hydrogen, alkyl, halogenoalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl;
Ry and Rz are each selected independently of the following (i) or (ii):
(i) Ry and Rz are each independently hydrogen, alkyl, halogenoalkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenyl alkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; or
(ii) Ry and Rz, together with the nitrogen atom to which they are attached, form a heterocyclyl or heteroaryl, optionally substituted with one or more, or 1, 2 or 3 Q7 groups; each Q7 is independently selected from halogen, deuterium, oxo, thioxo, hydroxy, alkoxy, alkyl, halogenoalkyl, hydroxyalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaryl, heterocyclyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl, heterocyl
J is O, NRx or S;
each t is independently an integer from 0-2;
n is 1o 2; Y
q is an integer from 0-4,
wherein the compounds are selected so that when W is CH; W1 is C; Z is S; R1 is hydrogen,
or hydroxyl and R2 is hydrogen, or R1 and R2 together form = O; Ring A is not pyridine.
Also described herein are compounds of formula I wherein ring A is heteroaryl, n is 1 and the other variables are as described elsewhere herein. Also described herein are compounds of formula I wherein ring A is heteroaryl, W1 is N, n is 1 or 2 and the other variables are as described elsewhere herein. Also described herein are compounds of formula I wherein ring A is heteroaryl, W1 is C or N, n is 1 or 2 and the other variables are as described elsewhere herein.
Compounds of formula I wherein the ring A is bicyclic or tricyclic heteroaryl are also described herein, and the other variables are as described elsewhere herein.
Also described herein are compounds of formula I or their pharmaceutically acceptable salts, solvates, hydrates, clathrates, individual stereoisomers, stereoisomers mixture or racemic mixture, wherein:
R1 and R2 are each independently selected from hydrogen, halogen, hydroxyl and alkoxy;
R3 is hydrogen or alkyl;
R4 is cycloalkyl, cycloalkenyl, aryl, heterocyclyl or heteroaryl, where R4 is optionally substituted with one or more, or 1 to 3, or 1, 2 or 3 groups selected from Q1;
12 5
10
fifteen
twenty
25
30
35
40


each Q1 is independently halogen, oxo, alkyl, halogenoalkyl, hydroxyalkyl, cycloalkyl, = NOH, -RuORx or -RuC (O) Rx;
Y is - (CR5R6) q-; R5 and R6 are each independently hydrogen, halogen, alkyl, halogenoalkyl or hydroxyalkyl; Z is O, S or NR7; R7 is hydrogen or alkyl; each W is independently CR8 or N; R8 is hydrogen, halogenoalkyl or alkyl; Ring A is aryl or heteroaryl, optionally substituted with 1 to 4 substituents selected from Q2; W1 is N or C;
W2 is N, NR9a or CR9b;
W3 is N, NR10a or CR10b;
W4 is N, NR11a or CR11b;
R9a, R9b, R10a, R10b, R11a and R11b are selected as follows:
i) R9a, R10a and R11a are each independently hydrogen or alkyl, and R9b, R10b and R11b are each independently hydrogen, oxo, hydroxyl, halogen or alkyl; or
ii) R9a and R10b, R9a and R10a, R9b and R10b, R9b and R10a, R10a and R11a, R10b and R11a, R10a and R11b or R10b and R11b together with the atoms to which they are attached form an aryl ring, heteroaryl or heterocyclyl, optionally substituted with one or more, or 1 to 3, or 1, 2 or 3 groups selected from Q2; and the rest of R9a, R10a and R11a are each
R9b R10b R11b
one independently hydrogen or alkyl; and the rest of y are each independently hydrogen, halogen or alkyl;
Each Q2 is independently halogen, cyano, oxo, thioxo, alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocycluoro-Ryu-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-alkyl-R-alkyl-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-C-N-R-alkyl-R-N-alkyl-R-N-R 1 -C (Rz), -RuN (Ry) (Rz), -RuSRx, -RuC (J) Rx, -RuC (J) ORx, -RuC (J) N (Ry) (Rz), -RuC (J) N ( Ry) ORx, -RuS (O) tRw, -RuN (Rx) C (J) Rx, -RuN (Rx) C (J) ORx, -RuN (Rx) S (O) tRw or -C (= NRy) N (Ry) ORx, where the alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl groups are optionally substituted with one or more Q4 groups; or from 1 to 3 groups Q4, each Q4 is independently selected from halogen, hydroxyl, alkyl, halogenoalkyl and hydroxyalkyl;
each Ru is independently alkylene or a direct bond;
Rw is alkyl;
each Rx is independently hydrogen or alkyl;
Ry and Rz are each independently hydrogen or alkyl;
J is O, NRx or S;
each t is independently an integer from 0-2;
n is 1 or 2; Y
q is an integer from 0-4,
wherein the compounds are selected so that when W is CH; W1 is C; Z is S; R1 is hydrogen, or hydroxyl and R2 is hydrogen, or R1 and R2 together form = O; Ring A is not pyridine.
The compounds of formula I are selected so that when W is CH; W1 is C; Z is NH; R1 and R2 together form = O; and q is 0, ring A is not phenyl. The compounds of formula I are selected so that when i) W is CH; W1 is C; Z is S; R1 is hydrogen or hydroxyl and R2 is hydrogen, or R1 and R2 together form = O; Ring A is not pyridine and ii) when W is CH; W1 is C; Z is NH; R1 and R2 together form = O; and q is 0, ring A is not phenyl.
13
image9
image10
image11
5
10
fifteen
twenty
25
30
35
40
Four. Five


For example, W1 is N. For example, W1 is C.
For example, W2 is N or CR9b, where R9b is hydrogen oxo, hydroxyl or alkyl. For example, W3 is N or CR10b, where R10b is hydrogen or alkyl. For example, W4 is N or CR11b, where R11b is hydrogen or alkyl. For example, W2 is CR9b; W3 is CR10b; W4 is N or CR11b; where R9b and R10b together with the carbon atoms to which they are substituents form an aryl or heteroaryl ring, optionally substituted with one or more, or 1 to 3, or 1, 2 or 3 groups selected from Q2; R11b is hydrogen or alkyl;
Each Q2 is independently halogen, cyano, oxo, thioxo, alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocycluoro-Ryu-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-alkyl-R-alkyl-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-C-N-R-alkyl-R-N-alkyl-R-N-R 1 -C (Rz), -RuN (Ry) (Rz), -RuSRx, -RuC (J) Rx, -RuC (J) ORx, -RuC (J) N (Ry) (Rz), -RuC (J) N ( Ry) ORx, -RuS (O) tRw, -RuN (Rx) C (J) Rx, -RuN (Rx) C (J) ORx, -RuN (Rx) S (O) tRw or -C (= NRy) N (Ry) ORx, where the alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl groups are optionally substituted with one or more Q4 groups; each Q4 is independently selected from halogen, hydroxyl, alkyl, halogenoalkyl and hydroxyalkyl;
each Ru is independently alkylene or a direct bond;
Rw is alkyl;
each Rx is independently hydrogen or alkyl;
Ry and Rz are each independently hydrogen or alkyl;
J is O, NRx or S; Y
Each t is independently an integer from 0-2.
For example, W2 is CR9b; W3 is CR10b; W4 is N; where R9b and R10b together with the carbon atoms in which they are substituents form an aryl or heteroaryl ring, optionally substituted with one or two groups selected from Q2, where Q is as defined elsewhere herein. For example, each Q2 is independently halogen, cyano, alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, -RuORx, -RuN (Ry) (Rz), -RuSRx, -RuC (J) Rx, - RuC (J) ORx, -RuC (J) N (Ry) (Rz), -RuC (J) N (Ry) ORx, -RuS (O) tRw, -RuN (Rx) C (J) Rx, -RuN (Rx) C (J) ORx, -RuN (Rx) S (O) tRw or -C (= NRy) N (Ry) ORx, where the alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl groups, and heterocyclyl are optionally substituted with one or more Q4 groups; each Q4 is independently selected from halogen, hydroxyl, alkyl, halogenoalkyl and hydroxyalkyl;
each Ru is independently alkylene or a direct bond;
Rw is alkyl;
each Rx is independently hydrogen or alkyl;
Ry and Rz are each independently hydrogen or alkyl;
J is O, NRx or S; Y
Each t is independently an integer from 0-2.
For example, n is 1 or 2. For example, n is 1. For example, n is 2.
For example, q is an integer from 0-4. For example, q is 0-3. For example, q is 0-2. For example, q is 0, 1 or 2. For example, q is 0. For example, q is 1. For example, q is 2.
Compounds of formula I or their pharmaceutically acceptable salts, solvates, hydrates, clathrates, individual stereoisomers, stereoisomers mixture or racemic mixture, are described herein where:
R1 and R2 are each independently selected from hydrogen, alkoxy and halogen;
R3 is hydrogen or alkyl;
R4 is cycloalkyl, aryl, heterocyclyl or heteroaryl, where R4 is optionally substituted with one or more, or 1 to 3, or 1, 2 or 3 groups selected from Q1;
each Q1 is independently halogen, oxo, alkyl, halogenoalkyl, hydroxyalkyl, cycloalkyl, = NOH, -RuORx or -RuC (O) Rx;
Y is direct link or - (CR5R6) q-;
17 5
10
fifteen
twenty
25
30
35
40


R5 and R6 are each independently hydrogen, halogen, alkyl, halogenoalkyl or hydroxyalkyl; Z is O, S, or NR7; R7 is hydrogen or alkyl; each W is independently CR8 or N; R8 is hydrogen, halogenoalkyl or alkyl; ring A is aryl or heteroaryl; W1 is N or C;
W2 is N, NR9a or CR9b;
W3 is N, NR10a or CR10b;
W4 is N, NR11a or CR11b;
R9a, R9b, R10a, R10b, R11a and R11b are selected as follows:
i) R9a, R10a and R11a are each independently hydrogen or alkyl; and R9b, R10b and R11b are each independently hydrogen, oxo, hydroxyl, halogen or alkyl; or
ii) R9a and R10b, R9a and R10a, R9b and R10b, R9b and R10a, R10a and R11a, R10b and R11a, R10a and R11b or R10b and R11b together with the atoms to which they are attached form an aryl or heteroaryl ring, optionally substituted with one or more, or 1 to 3, or 1, 2 or 3 groups selected from Q2; the rest of R9a, R10a and R11a are each
R10b and R11b
independently hydrogen or alkyl; the rest of R9b are each independently
hydrogen, halogen or alkyl; Each Q2 is independently halogen, cyano, oxo, thioxo, alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocycluoro-Ryu-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-alkyl-R-alkyl-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-R-alkyl-R-N-alkyl-R-N-alkyl-R-N-alkyl-R-N-R-C-N-R-alkyl-R-N-alkyl-R-N-R 1 -C (Rz), -RuN (Ry) (Rz), -RuSRx, -RuC (J) Rx, -RuC (J) ORx, -RuC (J) N (Ry) (Rz), -RuC (J) N ( Ry) ORx, -RuS (O) tRw, -RuN (Rx) C (J) Rx, -RuN (Rx) C (J) ORx, -RuN (Rx) S (O) tRw or -C (= NRy) N (Ry) ORx, where the alkyl, halogenoalkyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with one or more Q4 groups; each Q4 is independently selected from halogen, hydroxyl, alkyl, halogenoalkyl and hydroxyalkyl;
each Ru is independently alkylene or a direct bond; Rw is alkyl; each Rx is independently hydrogen or alkyl; Ry and Rz are each independently hydrogen or alkyl; J is O, NRx or S; each t is independently an integer from 0-2; n is 1; and q is an integer from 0-2.
Compounds of formula II are described herein
image12
or its pharmaceutically acceptable salts, solvates, hydrates, clathrates, individual stereoisomers, mixture of stereoisomers or racemic mixture, wherein: R1 and R2 are each independently selected from hydrogen, alkoxy and halogen;
R3 is hydrogen or alkyl; 18
image13
image14
image15
image16
image17
image18
image19
image20
image21
image22
image23
image24
image25
image26
image27
image28
image29
image30
image31
image32
image33
image34
image35
image36
image37
image38
image39
image40
image41
image42
image43
image44
image45
image46
image47
image48
image49
image50
image51
image52
image53
image54
image55
image56
image57
image58
image59
image60
image61
image62
image63
image64
image65
image66
image67
image68
image69
image70
image71
image72
image73
image74
image75
image76
image77
image78
image79
image80
image81
image82
image83
image84
image85
image86
image87
image88
image89
image90
image91
image92
image93
image94
image95
image96
image97
image98
image99
image100
image101
image102
image103
image104
image105
image106
image107
image108
image109
image110
image111
image112
image113
image114
image115
image116
image117
image118
image119
image120
image121
image122
image123
5
10
fifteen
twenty
25
30
35
40
Four. Five
The mixture was heated at reflux for 2 h, and then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 100% EtOAc to give 6 - ((5-bromo-6-methoxy-1Hbenzo [d] imidazol-1-yl) methyl) -2- (methylthio) benzo [d] thiazole (50 mg, 40%) in the form of an oil. 1H NMR (300 MHz, CDCl3) δ 8.01 (s, 1H), 7.78-7.91 (m, 2H), 7.46 (s, 1H), 7.25 (m, 1H), 6 , 69 (s, 1H), 5.42 (s, 2H), 3.81 (s, 3H), 2.78 (s, 3H). LCMS (ESI) m / z 420 and 422 (M + H) +.
Stage 4: The 6 - ((5-bromo-6-methoxy-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole was synthesized in the form of a white foam ( 75 mg) using a procedure analogous to that described in step 6 of example 36, substituting the 6 - ((4-bromo-1 H -imidazol-1-yl) methyl) -2- (methylthio) benzo [d] thiazole used in Example 36 for the 6 - ((5-bromo-6-methoxy-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylthio) benzo [d] thiazole step 3 of this example. LCMS (ESI) m / z 436 and 438 (M + H) +.
Stage 5: (1R, 2R) -2 - ((6 - ((5-bromo-6-methoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol was synthesized in the form of a white powder (15 mg, 26%) using a procedure analogous to that described in step 4 of example 37, substituting N-methyl-1 - ((2- (methylsulfinyl) benzo [d ] thiazol-6-yl) methyl) -1H-imidazol-4-carboxamide used in example 37 by 6 - ((5-bromo-6-methoxy-1H-benzo [d] imidazol-1-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole of step 4 of this example. 1H NMR (300 MHz, DMSO-d6) δ 8.29 (s, 1H), 7.98 (d, J = 7.5 Hz, 1H), 7.85 (s, 1H), 7.66 (d , J = 1.1 Hz, 1H), 7.37 (s, 1H), 7.27-7.33 (m, 1H), 7.22 (dd, J = 9, 1.5 Hz, 1H) , 5.46 (s, 2H), 4.75 (d, J = 4.9 Hz, 1H), 3.85 (s, 3H), 3.52 (wide m, 1H), 3.33 (m width, 1H), 2.02 (m width, 1H), 1.85 (m width, 1H), 1.55 -1.68 (m width, 2H), 1.10 -1.34 (m width, 4H). LCMS (ESI) m / z 487 and 489 (M + H) +.
Comparative example
Preparation of (1R, 2R) -1 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -2,3-dihydro-1Hinden-2-ol
image124
A stirred mixture of 6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole of Example 29 (210 mg, 0, 3 mmol), (1R, 2R) -1-amino-2,3-dihydro-1H-inden-2-ol (92 mg, 0.6 mmol) and DIEA (267 µl, 1.5 mmol) in DMA ( 3 ml) was heated at 130 ° C for 120 h in a tightly sealed tube. The mixture was cooled to t.a. and was subjected to preparative reverse phase HPLC purification using a mixture of water (5% CH3CN, 0.05% HCOOH) and CH3CN (0.05% HCOOH) as the mobile phase and Varian Pursuit XRs C18 column as the stationary phase to give the (1R, 2R) -1 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2- il) amino) -2,3dihydro-1H-inden-2-ol (5.4 mg, 4%) as a white powder. 1H NMR (300 MHz, DMSO-d6) δ 8.68 (s, 1H), 8.36 8.54 (m, 3H), 7.71 (s, 1H), 7.35 (m, 1H), 7.11 -7.30 (m, 5H), 5.51 (s, 2H), 5.18 (t, J = 7.0 Hz, 1H), 4.30 (m, 1H), 3.16 (dd, J = 7.2, 15.8 Hz, 1H), 2.74 (dd, J = 7.3, 15.4 Hz, 1H). LCMS (ESI) m / z 492 and 494 (M + H) +.
Example 43
Preparation of 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-6carbonitrile
image125
A stirred mixture of (1R, 2R) -2 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2il) amino) cyclohexanol of example 29 (170 mg, 0.372 mmol), zinc cyanide (131 mg, 1.12 mmol), 1,1'bis (diphenylphosphino) ferrocene (31 mg, 0.0558 mmol) and anhydrous DMF (2 ml) was degassed under argon for 15 min. Tris (dibenzylidenacetone) dipaladium (0) (34 mg, 0.0372 mmol) was added. The reaction vessel was sealed and the mixture was heated at 100 ° C for 6 h. After cooling to rt, the mixture was purified directly by reverse phase HPLC using a mixture of water (5% CH3CN, 0.05% HCOOH) and CH3CN (0.05% HCOOH) as the mobile phase and column. Varian Pursuit XRs C-18 vary as the stationary phase to give the ((2 (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5 -b] pyridine-6-carbonitrile (51 mg, 34%) in the form of a white solid. 1H NMR (300 MHz, DMSO-d6) δ 8.80 -8.91 (m, 2H), 8.72 (d, J = 1.5 Hz, 1H), 7.99 (d, J = 7, 3 Hz, 1H), 7.68 (s, 1H), 7.20 -7.34 (m, 2H), 5.53 (s, 2H), 4.74 (wide s, 1H), 3.29 -3.38 (m, 2H), 2.04 (m, 1H), 1.88 (m, 1H), 1.55 -1.70 (m, 2H), 1.10 -1.35 (m , 4H). LCMS (ESI) m / z 405 (M + H) +.
130
image126
image127
image128
image129
image130
image131
image132
image133
extracted with DCM (2 x 50 ml). The combined organic layers were washed with brine, dried over MgSO4 and concentrated under reduced pressure. The residue was purified by preparative TLC on silica gel, eluting with 2N NH3 / MeOH: EtOAc 5:95, followed by HPLC using a mixture of water (5% CH3CN, 0.05% HCOOH) and CH3CN (0 , 05% of HCOOH) as the mobile phase and Varian Pursuit XRs C-18 column as the stationary phase for
5 give two separate diastereoisomers:
The first isomer that elutes in reverse phase HPLC is one of (1S, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3yl) methyl) benzo [d] thiazole- 2-yl) amino) -1-methylcyclohexanol or (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3yl) methyl) benzo [d] thiazol-2-yl ) amino) -1-methylcyclohexanol
(5 mg, 8%) in the form of a white powder. 1H NMR (300 MHz, MeOH-d4) δ 8.40 -8.51 (m, 2H), 8.10 (dd, J = 0.9, 8.1
10 Hz, 1H), 7.64 (s, 1H), 7.23-7.43 (m, 3H), 5.57 (s, 2H), 3.78 -3.92 (m, 1H), 1.56-1.84 (m, 4H), 1.31-1.55 (m, 4H), 1.22 (s, 3H). LCMS (ESI) m / z 394 (M + H) +.
Example 60
Preparation of (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -1-methylcyclohexanol or (1S, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -1-methylcyclohexanol
image134
fifteen
For the two diastereoisomers obtained in Example 59, the second isomer eluting in reverse phase HPLC is one of (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridine) 3-yl) methyl) benzo [d] thiazol-2-yl) amino) -1-methylcyclohexanol or (1S, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3) -yl) methyl) benzo [d] thiazol-2-yl) amino) -1-methylcyclohexanol and is the alternative to example 59; obtained in the form of a white powder (4 mg, 6%). 1H NMR (300 MHz, MeOH-d4) δ 8.28-8.40 (m,
20 2H), 7.99 (dd, J = 1.1, 8.1 Hz, 1H), 7.52 (d, J = 0.9 Hz, 1H), 7.13-7.35 (m, 3H), 5.45 (s, 2H), 3.58 (dd, J = 3.9, 11.2 Hz, 1H), 1.17 -1.74 (m, 8H), 1.12 (s , 3H). LCMS (ESI) m / z 394 (M + H) +.
Example 61
Preparation of (1R, 2R) -2 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] oxazol-2-yl) amino) cyclohexanol
image135
Step 1: A stirred mixture of 5-bromopyridine-2,3-diamine (5 g, 26.6 mmol), formic acid (2.5 ml), and triethyl orthoformate (70 ml) was heated at 100 ° C for 2 , 5 h. The reaction mixture was cooled to t.a. and the precipitated solid was collected by filtration, washed with Et2O and dried to give 6-bromo-3H-imidazo [4,5-b] pyridine as a solid (3.22 g, 61%) which did not required additional purification. 1H NMR (300 MHz, DMSO-d6) δ 13.14 (broad s, 1H), 8.50 (s, 1H), 8.44 (d, J = 2.1 Hz, 1H), 8.31 ( d, J = 1.9 Hz, 1H). LCMS (ESI) m / z 198 and 200 (M + H) +.
Step 2: At a stirred solution of 6-bromo-3H-imidazo [4,5-b] pyridine (506 mg, 2.55 mmol) of step 1 of this example in anhydrous DMF (10 ml) at 0 ° C Sodium hydride (60% dispersion in mineral oil, 107 mg, 2.68 mmol) was added in one portion, and the mixture was stirred at 0 ° C for 30 min. To the reaction mixture was added a solution of 6- (chloromethyl) -2- (methylthio) benzo [d] oxazole (600 mg, 2.81 mmol) of step 3 of example 56 in DMF (2 ml). The mixture was allowed to warm to t.a., then stirred for a further 15 h. Water was added to the reaction mixture and the mixture was
35 extracted with EtOAc. The organic layer was separated and the aqueous layer was extracted with more EtOAc. The combined organic layers were washed with water and then brine. The organic layer was separated, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 100% DCM, followed by MeOH in 1% DCM to give 6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3 -il) methyl) -2 (methylthio) benzo [d] oxazole (460 mg, 48%) as a white solid. The alkylation regiochemistry was determined
40 per experiment of two-dimensional nuclear Overhauser (NOE) effect. 1H NMR (300 MHz, DMSO-d6) δ 8.70 (s, 1H),
139
image136
image137
image138
image139
image140
image141
image142
image143
image144
The filtrate was concentrated under reduced pressure, and the residue was purified by flash chromatography on silica gel eluting with 100% DCM to MeOH in 10% DCM to give 3H-imidazo [4,5-b] pyridine-6-carboxylate. Additional methyl (550 mg, 31%) in the form of a cream-colored solid. 1H NMR (300 MHz, DMSO-d6) δ 13.33 (broad s, 1H), 8.95 (d, J = 1.5 Hz, 1H), 8.64 (s, 1H), 8.50 ( d, J = 1.5 Hz, 1H), 3.91 (s, 3H). LCMS (ESI) m / z 178 (M + H) +.
Step 3: To a stirred solution of methyl 3H-imidazo [4,5-b] pyridine-6-carboxylate (1.34 g, 7.56 mmol) of step 2 of this example in anhydrous DMF (25 ml ) at 0 ° C was added in a portion sodium hydride (60% dispersion in mineral oil, 333 mg, 8.32 mmol) and the mixture was stirred at 0 ° C for 30 min. To the reaction mixture was added a solution of 6- (chloromethyl) -2- (methylthio) benzo [d] thiazole (1.3 g, 5.66 mmol) of step 4 of example 36 in DMF (5 ml) . The mixture was allowed to warm to t.a. then it was stirred for an additional 15 h. Water was added to the reaction mixture
10 (300 ml) and the mixture was extracted with EtOAc (3 × 50 ml). The combined organic layers were washed with water and then brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 100% DCM followed by MeOH in 1% DCM to give 3 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) - Methyl 3H-imidazo [4,5-b] pyridine-6-carboxylate (1.3 g, 46%) as a white solid. The alkylation regiochemistry was determined by Overhauser nuclear effect experiment.
15 (NOE) two-dimensional. 1H NMR (300 MHz, DMSO-d6) δ 8.95 (d, J = 1.9 Hz, 1H), 8.81 (s, 1H), 8.56 (d, J = 1.7 Hz, 1H ), 8.00 (d, J = 1.1 Hz, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.47 (dd, J = 1.6, 8.4 Hz , 1H), 5.66 (s, 2H), 3.90 (s, 3H), 2.76 (s, 3H). LCMS (ESI) m / z 371 (M + H) +.
Step 4: To a stirred solution of 3 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-6-carboxylate methyl (300 mg , 0.811 mmol) of step 3 of this example in DCM (10 ml) at 0 ° C was added 70% meta20 chloroperbenzoic acid (154 mg, 0.892 mmol) and the mixture was allowed to warm to rt. and stirred for another 4 h. To the mixture was added saturated aqueous NaHO3 solution and the organic layer was separated. The aqueous layer was extracted with DCM and the combined organic layers were washed with saturated aqueous NaHCO3 solution. The organic layer was separated, dried over MgSO4, filtered, and concentrated under reduced pressure to give 370 mg of a 2: 1 mixture of 3- ((2- (methylsulfinyl) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] methyl pyridine-6-carboxylate and 3 - ((2
Methyl (methylsulfonyl) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-6-carboxylate in the form of an oil that was no longer purified. LCMS (ESI) m / z 387 (M + H) + (according to 3 - ((2- (methylsulfinyl) benzo [d] thiazol-6-yl) methyl) -3Himidazo [4,5-b] pyridine -6-methyl carboxylate) and m / z 403 (M + H) + (according to 3 - ((2 (methylsulfonyl) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5 -b] methyl pyridine-6-carboxylate).
Step 5: A 2: 1 mixture of 3 - ((2- (methylsulfinyl) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-6-carboxylate
Methyl and 3 - ((2- (methylsulfonyl) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-6-carboxylate methyl (360 mg) of step 4 from this example it was dissolved in anhydrous DMA (10 ml), and (1R, 2R) - (-) - 2-aminocyclohexanol (322 mg, 2.79 mmol) and DIEA (360 mg, 2.79 mmol) were added. The reaction vessel was sealed and the mixture was heated with stirring at 100 ° C for 19 h. The LCMS analysis indicated that the reaction was not complete. To the reaction mixture was added (1R, 2R) - (-) - additional 2-aminocyclohexanol (100 mg, 0.870 mmol) and the vessel
The reaction was sealed and the mixture was heated at 100 ° C for an additional 15 h. After the reaction mixture was cooled to rt, one half of the reaction mixture was purified directly by reverse phase HPLC using a mixture of water (5% CH3CN, 0.05% HOAc) and CH3CN (0.05% HOAc ) as the mobile phase and Varian Pursuit XRs-Diphenyl column as the stationary phase to give the 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6il) methyl) - Methyl 3H-imidazo [4,5-b] pyridine-6-carboxylate (19 mg) as a white solid. 1H NMR (300 MHz,
40 DMSO-d6) δ 8.96 (d, J = 7.3 Hz, 1H), 8.76 (m, 1H), 8.54 (m, 1H), 7.99 (wide s, 1H), 7.66 (d, J = 7.2 Hz, 1H), 7.16 7.33 (m, 2H), 5.51 (wide s, 2H), 4.76 (wide s, 1H), 3, 89 (s, 3H), 3.30-3.50 (m, 2H), 2.02 (m, 1H), 1.86 (m, 1H), 1.50 -1.70 (m, 2H) , 1.10 -1.30 (m, 4H). LCMS (ESI) m / z 438 (M + H) +.
Comparative example
Preparation of (1R, 2R) -1 - ((6 - ((5-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -2,3-dihydro-1H45 inden-2-ol
image145
A stirred mixture of 6 - ((5-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole (130 mg, 0.332 mmol) of the step 4 of example 78, (1R, 2R) - (-) - trans-1-amino-2-indanol (198 mg, 1.33 mmol), and DIEA (214 mg, 1.66 mmol) in anhydrous DMA ( 2 ml) in a tightly sealed reaction vessel was heated in a Biotage 50 microwave synthesizer at 140 ° C for 1.5 h. The LCMS analysis indicated that the reaction was incomplete. Additional (1R, 2R) - (-) - trans-1-amino-2-indanol (50 mg, 0.335 mmol) was added, and the mixture was heated in a Biotage microwave synthesizer at 140 ° C for an additional 45 min. The reaction mixture was cooled to t.a. and was purified directly by reverse phase HPLC using a mixture of water (5% CH3CN, 0.05% HOAc) and CH3CN (0.05% HOAc) as the mobile phase and Varian Pursuit XRs-Diphenyl column as the stationary phase to give (1R, 2R) -155 ((6 - ((5-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -2,3-dihydro-1H-inden-2-ol (24 mg, 15%) in
149
image146
image147
image148
image149
image150
image151
image152
image153
image154
image155
image156
image157
image158
image159
image160
image161
image162
image163
image164
image165
image166
image167
image168
image169
image170
g, 26 mmol). The reaction mixture was stirred at -10 ° C for 0.5 h. The mixture was poured into ice-water and extracted with EtOAc (100 ml × 3). The combined organic layers were washed sequentially with water, saturated aqueous NaHCO3 solution (100 ml × 2) and brine (100 ml). The organic layer was separated, dried over Na2SO4, filtered, and concentrated under reduced pressure to give 4-fluoro-N1 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) benzene- 1,2-diamine
5 (0.93 g, 87% yield) as a yellow solid, which was no longer purified. 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.4 Hz, 1H), 7.76 (s, 1H), 7.42 (dd, J = 8.4, 1.8 Hz , 1H), 6.42-6.56 (m, 3H), 4.35 (s, 2H), 3.60 (wide s, 2H), 2.79 (s, 3H); LCMS (ESI) m / z 320 (M + H) +.
Step 3: A stirred mixture of 4-fluoro-N4 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) benzene-1,2-diamine (0.93 g, 2.93 mmol) from the previous step, formic acid (0.5 ml) and triethyl orthoformate (5 ml) was heated at 100 ° C for 1 h. The
The reaction mixture was cooled to t.a. and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 3% MeOH in DCM to give 6 - ((5-fluoro-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylthio) benzo [ d] thiazole (0.64 g, 67%) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.99 (s, 1H), 7.83 (d, J = 8.1 Hz, 1H), 7.47-7.51 (m, 2H), 7.26 (m, 1H), 7.17 (m, 1H), 7.00 (dt, J = 9.3, 2.4 Hz, 1H), 5.44 (s, 2H), 2.77 (s, 3H); LCMS (ESI) m / z 330 (M + H) +.
Step 4: To a stirred solution of 6 - ((5-fluoro-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylthio) benzo [d] thiazole (0.64 g, 1, 9 mmol) of the previous step in DCM (20 ml) at 0 ° C a solution of meta-chloroperbenzoic acid (0.472 g, 2.3 mmol) in DCM (3 ml) was added. The mixture was stirred at 0 ° C for 2 h. The solution was diluted with EtOAc (100 ml) and washed sequentially with saturated aqueous Na2S2O3 solution, saturated aqueous NaHCO3 solution, and brine. The organic layer was separated, dried over Na2SO4, filtered, and concentrated under reduced pressure to give the
20 6 - ((5-fluoro-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole (0.63 g, 94%) as a yellow solid, That was not purified anymore. 1H NMR (300 MHz, CDCl3) δ 8.02 -8.05 (m, 2H), 7.78 (s, 1H), 7.51 (dd, J = 9.6, 2.4 Hz, 1H) , 7.38 (dd, J = 8.4, 1.8 Hz, 1H), 7.20 (m, 1H), 7.00 (dt, J = 9.0, 2.4 Hz, 1H), 5.52 (s, 2H), 3.07 (s, 3H); LCMS (ESI) m / z 346 (M + H) +.
Step 5: A stirred mixture of 6 - ((5-fluoro-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole (0.20 g,
25 0.57 mmol) of the previous step, (1R, 2R) -2-aminocyclohexanol (0.20 g, 1.7 mmol), DIEA (0.73 g, 5.7 mmol) and NMP (2 ml) , heated at 130 ° C for 12 h. The reaction mixture was cooled to t.a., diluted with EtOAc (30 ml), and washed with water (10 ml × 2). The organic layer was separated, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 3% MeOH in DCM to give the (1R, 2R) -2 - ((6 - ((5-fluoro-1H-benzo [d] imidazol-1- il) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol (75 mg,
30 33%) in the form of a white solid. 1H NMR (300 MHz, DMSO-d6) δ 8.45 (s, 1H), 7.93 (d, J = 7.2 Hz, 1H), 7.65 (d, J = 1.5 Hz, 1H ), 7.56 (m, 1H), 7.43 (dd, J = 9.6, 2.4 Hz, 1H), 7.28 (m, 1H), 7.19 (dd, J = 8, 4, 1.8 Hz, 1H), 7.08 (dt, J = 9.6, 3.0 Hz, 1H), 5.46 (s, 2H), 4.69 (d, J = 5.4 Hz, 1H), 3.51 (m, 1H), 3.37 (m, 1H), 2.01 (m, 1H), 1.87 (m, 1H), 1.59 1.63 (m, 2H), 1.15-1.23 (m, 4H); LCMS (ESI) m / z 397 (M + H) +.
Example 130
Preparation of (1R, 2R) -2 - ((6 - ((5- (trifluoromethyl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
image171
Stage 1: The N - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -2-nitro-4- (trifluoromethyl) aniline (0.38 g, 49%) was obtained as a yellow solid using a procedure analogous to that described in step 1 of example 127, substituting the 4-methyl-2-nitroaniline used in example 127 for 2-nitro-4- (trifluoromethyl) aniline. 1H NMR (300 MHz, CDCl3) δ 8.64
40 (wide s, 1H), 8.50 (s, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.71 (s, 1H), 7.56 (dd, J = 9.0, 2.1 Hz, 1H), 7.38 (dd, J = 8.4, 1.8 Hz, 1H), 6.90 (d, J = 9.0 Hz, 1H), 4, 69 (d, J = 5.7 Hz, 2H), 2.79 (s, 3H); LCMS (ESI) m / z 400 (M + H) +.
Stage 2: A mixture of N - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -2-nitro-4-trifluoromethyl) aniline (0.38 g, 2.0 mmol) of the previous step, MeOH (30 ml) and palladium on activated carbon (50 mg) was stirred under hydrogen atmosphere (1 atm) at
t.a. for 12 h. The mixture was filtered to remove the catalyst and the filtrate was concentrated under reduced pressure to give
45 N1 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -4- (trifluoromethyl) benzene-1,2-diamine (0.32 g, 91%) as a solid brown, which was not purified anymore. LCMS (ESI) m / z 370 (M + H) +.
Step 3: A stirred mixture of N1 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -4- (trifluoromethyl) benzene-1,2-diamine (0.32 g, 0.86 mmol) from the previous step, formic acid (0.5 ml) and triethyl orthoformate (5 ml) was heated at 100 ° C for 1
h. The reaction mixture was cooled to t.a. and concentrated under reduced pressure. The residue was purified by chromatography.
Ultrafast silica gel eluting with 3% MeOH in 3% DCM to give 2- (methylthio) -6 - ((5- (trifluoromethyl) -1Hbenzo [d] imidazol-1-yl) methyl) benzo [d] thiazole (0.22 g, 69%) in the form of a yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.12 (s, 1H), 8.08 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.48-7.54 (m, 2H), 7.36 (d, J = 8.4 Hz, 1H), 7.26 (m, 1H), 5.49 (s, 2H), 2.78 (s, 3H); LCMS (ESI) m / z 380 (M + H) +.
175
image172
image173
Step 1: To a stirred solution of 6-fluoro-3H-imidazo [4,5-b] pyridine (502 mg, 3.66 mmol) of step 2 of example 70 in anhydrous DMF (10 ml) at 0 ° C was added in a portion of sodium hydride (60% dispersion in mineral oil, 220 mg, 5.49 mmol), and the mixture was stirred at 0 ° C for 30 min. To the reaction mixture was added a solution of 6- (chloromethyl) -2- (methylthio) benzo [d] oxazole (858 mg, 4.03 mmol) of step 3 of example 56 in DMF (2 ml). The mixture was allowed to warm to t.a. and stir for another 3 h. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate (3 × 100 ml). The combined organic layers were washed sequentially with water and brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 30% to 50% ethyl acetate in petroleum ether to give the
10 6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) -2- (methylthio) benzo [d] oxazole (698 mg, 61%) as a solid White. The alkylation regiochemistry was determined by two-dimensional Overhauser (NOE) nuclear effect experiment. 1H NMR (300 MHz, DMSO-d6): δ 8.71 (s, 1H), 8.41 (s, 1H), 8.07 (d, J = 6. 9 Hz, 1H), 7.68 ( s, 1H), 7.58 (d, J = 7.8 Hz, 1H), 7.35 (d, J = 6.3 Hz, 1H), 5.59 (s, 2H), 2.73 ( s, 3H); LCMS (ESI) m / z315 (M + H) +.
Step 2: To a stirred solution of 6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) -2- (methylthio) benzo [d] oxazole (595
15 mg, 1.89 mmol) of the previous step in DCM (10 ml) at 0 ° C was added 70% meta-chloroperbenzoic acid (425 mg, 2.46 mmol). The reaction mixture was stirred at 0 ° C for 2 h. The reaction mixture was washed sequentially with aqueous sodium sulphite solution and brine. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 50% ethyl acetate in petroleum ether to give 6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) -2
20 (Methylsulfinyl) benzo [d] oxazole (509 mg, 82%). 1H NMR (300 MHz, DMSO-d6): δ 8.73 (s, 1H), 8.40 (s, 2H), 7.53 (d, J = 7.2 Hz, 1H), 7.37 ( s, 1H), 7.15 (d, J = 4.5 Hz, 1H), 5.69 (s, 2H), 3.18 (s, 3H); LCMS (ESI) m / z 331 (M + H) +.
Step 3: A stirred mixture of 6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) -2- (methylsulfinyl) benzo [d] oxazole (220 mg, 0, 67 mmol) from the previous step, (1R, 2R) -2-amino-cyclohexanol (152 mg, 1 mmol), and DIEA (259 mg, 2.01 mmol) in DMA (5 ml) was heated at 135 ° C for 2 h. The reaction mixture was cooled to t.a., poured into water (30 ml), and extracted into ethyl acetate (50 ml × 3). The combined organic layers were washed sequentially with water and brine. The organic layer was separated, dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was directly purified by preparative reverse phase HPLC to give the (1R, 2R) -2 - ((6 - ((6-fluoro-3Himidazo [4,5-b] pyridin-3-yl) methyl) benzo [ d] oxazol-2-yl) amino) cyclohexanol (68 mg, 27%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6): δ 8.67 (s, 1H), 8.41 (m, 1H), 8.06 (m, 1H), 7.79 (m, 1H), 7, 39 (s, 1 H), 7.13-7.15 (m,
30 2H), 5.48 (s, 2H), 4.67 (d, J = 3.9 Hz, 1H), 3.30 -3.35 (m, 2H), 1.86 -1.95 ( m, 2H), 1.60 -1.65 (m, 2H), 1.15 -1.35 (m, 4H); LCMS (ESI) m / z 382 (M + H) +.
Example 133
Preparation of ((1R, 2R) -2 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2yl) amino) cyclohexyl ) methanol
image174
35
Step 1: To a stirred solution of (1R R) -2-aminocyclohexanecarboxylic acid (500 mg, 3.49 mmol) in anhydrous THF (3 ml) at 0 ° C was added dropwise a solution of LAH (2M solution in THF , 7 ml, 13.99 mmol). The reaction vessel was sealed and the mixture was stirred at 85 ° C for 24 h. The mixture was cooled to 0 ° C and diluted with THF (6 ml). To the reaction mixture was added sequentially water (0.5 ml), aqueous solution of
40 M NaOH (0.5 ml), and water (1.5 ml). To the mixture was added MgSO4 and the mixture was stirred at t.a. for 10 min. The mixture was then diluted with THF (10 ml) and filtered, and the filtrate was concentrated under reduced pressure to give ((1R, 2R) -2-aminocyclohexyl) methanol (326 mg, 70%) as an oil . 1H NMR (300 MHz, DMSO-d6) δ 3.27 3.52 (m, 3H), 2.29 (dt, J = 10.1, 4.0Hz, 1H), 1.53 -1.78 ( m, 4H), 0.98 -1.21 (m, 4H), 0.87 (m, 1H).
Stage 2: The ((1R, 2R) -2 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl ) amino) cyclohexyl) methanol
45 (18 mg, 18%) was obtained in the form of a solid using a procedure analogous to that described in step 5 of Example 70, substituting 6 - ((6-fluoro-3 H -imidazo [4,5-b] pyridine) -3-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole used in example 70 by 6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl ) -2- (methylsulfinyl) benzo [d] thiazole of step 4 of example 29, and replacing the (1R, 2R) -2-aminocyclohexanol used in example 70 with the ((1R, 2R) -2aminocyclohexyl) methanol of Stage 1 of this example. 1H NMR (500 MHz, DMSO-d6) δ 8.65 (s, 1H), 8.48 (d, J = 2.0
50 Hz, 1H), 8.39 (d, J = 2.0 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 1.0 Hz , 1H), 7.28 (m, 1H), 7.22 (m, 1H), 5.47
177
image175
5
10
fifteen
twenty
25
30
35
40
Stage 2: The ((1S, 2R) -2 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl ) amino) cyclohexyl) methanol (7 mg, 19%) was obtained in the form of a solid using a procedure analogous to that described in step 5 of example 70, substituting 6 - ((6-fluoro-3 H -imidazo [4, 5-b] pyridin-3-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole used in example 70 by 6 - ((6-bromo-3H-imidazo [4,5-b] pyridin- 3-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole of step 4 of example 29, and substituting the (1R, 2R) -2-aminocyclohexanol used in example 70 for the ((1S, 2R) -2-aminocyclohexyl) methanol from step 1 of this example. 1H NMR (500 MHz, DMSO-d6) δ 8.66 (s, 1H), 8.48 (d, J = 2.0 Hz, 1H), 8.39 (d, J = 2.0 Hz, 1H ), 7.92 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 1.0 Hz, 1H), 7.28 (m, 1H), 7.23 (m, 1H ), 5.48 (s, 2H), 4.61 (wide s, 1H), 4.23 (wide s, 1H), 3.27 (m, 1H), 3.21 (m, 1H), 1 , 81 (m, 1H), 1.74 (m, 1H), 1.63 (m, 1H), 1.39-1.52 (m, 4H), 1.21 1.37 (m, 2H) ; LCMS (ESI) m / z 472, 474 (M + H) +.
Example 137
Preparation of (1R, 2R) -2 - ((6 - ((5,6-dichloro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
image176
Stage 1: 5,6-Dichloro-N - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -3-nitropyridin-2-amine (105 mg) was obtained as a solid yellow using a procedure analogous to that described in step 5 of example 23, substituting the 2-chloro-6-methoxy-3-nitropyridine used in example 23 for 2,3,6-trichloro-5-nitropyridine. LCMS (ESI) m / z 401, 403, 405 (M + H) +.
Stage 2: The (1R, 2R) -2 - ((6 - ((5,6-dichloro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2- il) amino) cyclohexanol (35 mg, 31%) was obtained using procedures similar to those described in step 6-9 of example 23, replacing 6-methoxy-N2 - ((2- (methylthio) benzo [d] thiazole -6-yl) methyl) pyridine-2,3-diamine used in step 6 of example 23 by 5,6-dichloro-N - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) - 3-nitropyridin-2-amine from step 1 of this example, and making analogous substitutions in subsequent stages. 1H NMR (500 MHz, DMSO-d6) δ 8.69 (s, 1H), 8.52 (s, 1H), 7.98 (d, J = 7.9 Hz, 1H), 7.63 (s , 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.19 (d, J = 7.9 Hz, 1H), 5.45 (s, 2H), 4.74 (s width, 1H), 3.51 (s width, 1H), 2.03 (d, J = 11.8 Hz, 1H), 1.86 (s width, 1H), 1.52 -1.69 (m , 2H), 1.06 -1.34 (m, 4H). LCMS (ESI) m / z 448, 450, 452 (M + H) +.
Example 138
Preparation of (1R, 2R) -2 - ((6 - ((5-ethoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
image177
A mixture of 1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1H-benzo [d] imidazol-5-ol (80 mg , 0.20 mmol) of example 147, iodoethane (47 mg, 0.30 mmol) and Cs2CO3 (196 mg, 0.6 mmol) in NMP (3.5 ml) was stirred at rt for 5 h. The mixture was added to water and extracted with DCM. The organic layer was separated, washed sequentially with water and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC to give the (1R, 2R) -2 - ((6 - ((5-ethoxy-1H-benzo [d] imidazol-1yl) methyl) benzo [d] thiazol-2 -il) amino) cyclohexanol (35 mg, 42%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 8.30 (s, 1H), 7.96 (d, J = 7.5 Hz, 1H), 7.62 (s, 1H), 7.39 (d , J = 9.0 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 7.14 -7.19 (m, 2H), 6.82 (d, J = 9, 0 Hz, 1H), 5.41 (s, 2H), 4.72 (d, J = 4.8 Hz, 1H), 3.97 -4.04 (m, 2H), 3.43 -3, 54 (m, 2H), 2.03 (m, 1H), 1.87 (m, 1H), 1.60 -1.65 (wide m, 2H), 1.32 (t, J = 13.8 Hz, 3H), 1.15 -1.24 (m, 4H). LCMS (ESI) m / z 423 (M + H) +.
Example 139
Preparation of 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-5,6dicarbonitrile
179
image178
3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-5,6- dicarbonitrile was obtained in the form of a white powder (7 mg, 21%) using procedures analogous to those described in example 43, substituting (1R, 2R) -2 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
5 used in Example 43 by (1R, 2R) -2 - ((6 - ((5,6-dichloro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol of Example 137. 1 H NMR (500 MHz, DMSO-d 6) δ 9.10 (s, 1 H), 9.03 (s, 1 H), 8.08 (d, J = 7, 4 Hz, 1H), 7.66 (s, 1H), 7.27-7.36 (m, 1H), 7.24 (d, J = 8.4 Hz, 1H), 5.56 (s, 2H), 4.84 (broad s, 1H), 3.46 -3.64 (m, 2H), 2.03 (d, J = 11.8 Hz, 1H), 1.87 (d, J = 10.8 Hz, 1H), 1.51 -1.70 (m, 2H), 1.08 -1.39 (m, 4H). LCMS (ESI) m / z 430 (M + H) +.
10 Example 140
Preparation of 3 - ((2 - (((1R, 2R) -2- (hydroxymethyl) cyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine- 6carbonitrile
image179
3 - ((2 - (((1R, 2R) -2- (hydroxymethyl) cyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-6 -carbonitrile se
15 obtained in the form of a solid (18 mg, 19%) using a procedure analogous to that described in example 43, substituting (1R, 2R) -2 - ((6 - ((6-bromo-3H-imidazo [4 , 5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol used in example 43 by the ((1R, 2R) -2 - ((6 - ((6- Bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2yl) amino) cyclohexyl) methanol of example 133. 1 H NMR (500 MHz, DMSO-d6) δ 8, 84 (s, 1H), 8.82 (d, J = 1.5 Hz, 1H), 8.72 (d, J = 1.5 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.67 (s, 1H), 7.28 (m, 1H), 7.24 (m, 1H), 5.53 (s, 2H), 4.46 (wide m,
20 1H), 3.55 (m wide, 1H), 3.41 (d, J = 9.8 Hz, 1H), 3.30 (m, 1H), 1.98 (m, 1H), 1, 83 (d, J = 10.8 Hz, 1H), 1.62 -1.73 (m, 2H), 1.37 (m, 1H), 1.17-1.27 (m, 4H); LCMS (ESI) m / z 419 (M + H) +.
Example 141
Preparation of (1R, 2R) -2 - ((6 - ((6- (1H-pyrazol-1-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2il) amino) cyclohexanol
image180
25
To a stirred solution of CuI (14 mg, 0.0053 mmol), K2CO3 (102 mg, 0.74 mmol), and pyrazole (30 mg, 0.44 mmol) in 2 ml of DMF under argon was added ( 1,2R) -2 - ((6 - ((6-iodo-3 H -imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol of step 2 from example 96 (150 mg, 0.30 mmol) and trans-N1, N2-dimethylcyclohexane-1,2-diamine (21 mg, 0.15 mmol). The reaction mixture was then heated at 110 overnight. The mixture was cooled to rt, diluted with MeOH, and purified by preparative HPLC using a mixture of water (5% CH3CN, 0.05% AcOH) and CH3CN (0.05% AcOH) as the mobile phase and column. They vary Pursuit XRs-Diphenyl as the stationary phase to give the (1R, 2R) -2 - ((6 - ((6- (1H-pyrazol-1-yl) -3H-imidazo [4,5-b] pyridin- 3il) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol (85 mg, 64%) as a white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.92 (d, J = 2.0 Hz, 1H), 8.69 (s, 1H), 8.57 (d, J = 2.5 Hz, 1H ), 8.50 (d, J = 2.5 Hz, 1H), 7.96 (d, J = 7.4 Hz,
1H), 7.79 (s, 1H), 7.68 (s, 1H), 7.29 (s, 1H), 7.20-7.27 (m, 1H), 6.58 (s, 1H), 5.52 (s, 2H), 4.74 (wide s, 1H), 3.51 (wide s, 1H), 2.03 (d, J = 12.3 Hz, 1H), 1, 80 -1.95 (m, 1H), 1.52 -1.72 (m, 2H), 1.08 -1.33 (m, 4H). LCMS (ESI) m / z 446 (M + H) +.
Example 142
180
image181
image182
image183
image184
5
fifteen
25
35
Four. Five
Stage 3: 2- (Methylthio) -6 - ((5- (trifluoromethoxy) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazole (0.55 g, 79%) was obtained in the form of a yellow solid using a procedure analogous to that described in step 3 of example 130, substituting N1 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -4- (trifluoromethyl) benzene -1,2-diamine used in example 130 by the N1 ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -4- (trifluoromethoxy) benzene-1,2-diamine step 2 of this example. 1H NMR (300 MHz, CDCl3) δ 8.03 (s, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.70 (s, 1H), 7.52 (s, 1H ), 7.22-7.28 (m, 2H), 7.13 (m, 1H), 5.45 (s, 2H), 2.78 (s, 3H); LCMS (ESI) m / z 396 (M + H) +.
Stage 4: 2- (Methylsulfinyl) -6 - ((5- (trifluoromethoxy) -1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazole (0.55 g, 96%) was obtained in the form of a yellow solid using a procedure analogous to that described in step 4 of example 130, substituting 2- (methylthio) -6 - ((5- (trifluoromethyl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazole used in example 130 by 2- (methylthio) -6 - ((5- (trifluoromethoxy) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazole step 3 of this example. 1H NMR (300 MHz, CDCl3) δ 8.08 (s, 1H), 7.04 (d, J = 8.4 Hz, 1H), 7.79 (s, 1H), 7.71 (s, 1H ), 7.38 (dd, J = 8.4, 1.8 Hz, 1H), 7.24 (m, 1H), 7.13 (m, 1H), 5.52 (s, 2H), 3 , 06 (s, 3H); LCMS (ESI) m / z 412 (M + H) +.
Stage 5: (1R, 2R) -2 - ((6 - ((5- (trifluoromethoxy) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) Cyclohexanol (65 mg, 35%) was obtained as a white solid using a procedure analogous to that described in step 5 of example 130, substituting 2- (methylsulfinyl) -6 - ((5- (trifluoromethyl) -1H- benzo [d] imidazol-1-yl) methyl) benzo [d] thiazole used in example 130 by 2- (methylsulfinyl) -6 - ((5- (trifluoromethoxy) -1H-benzo [d] imidazol-1- il) methyl) benzo [d] thiazole of step 4 of this example. 1H NMR (300 MHz, DMSO-d6) δ 8.54 (s, 1H), 7.93 (d, J = 6.6 Hz, 1H), 7.65-7.75 (m, 3H), 7 , 30 (d, J = 8.1 Hz, 1H), 7.21-7.26 (m, 2H), 5.50 (s, 2H), 4.69 (d, J = 5.1 Hz, 1H), 3.51 (m, 1H), 3.40 (m, 1H), 2.01 (m, 1H), 1.85 (m, 1H), 1.57-1.60 (m, 2H ), 1.20 -1.23 (m, 4H); LCMS (ESI) m / z 463 (M + H) +.
Example 150
Preparation of (1R, 2R) -2 - ((6 - ((6-methoxyimidazo [1,2-b] pyridazin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
image185
Stage 1: A stirred mixture of 2-chloro-3- (2- (methylthio) benzo [d] thiazol-6-yl) propanal from step 4 of example 117 (600 mg, 2.2 mmol) and 6-methoxypyridazin -3-amine (550 mg, 4.4 mmol) in 1-butanol (20 ml) was heated at reflux overnight. The mixture was cooled to t.a. and water (40 ml) was added. The mixture was extracted with EtOAc (20 ml × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with DCM / MeOH from 50: 1 to 20: 1 to give the 6 - ((6-methoxyimidazo [1,2-b] pyridazin-3-yl) methyl) -2 - (methylthio) benzo [d] thiazole in the form of a light brown solid (500 mg, 66%). 1H NMR (300 MHz, CDCl3) δ 7.79-7.73 (m, 2H), 7.67 (d, J = 1.2 Hz, 1H), 7.43 (s, 1H), 7.38 (dd, J = 1.5, 8.4 Hz, 1H), 6.64 (d, J = 9.6 Hz, 1H), 4.33 (s, 2H), 3.94 (s, 3H) , 2.78 (s, 3H). LCMS (ESI) m / z 343 (M + H) +.
Step 2: To a solution of 6 - ((6-methoxyimidazo [1,2-b] pyridazin-3-yl) methyl) -2- (methylthio) benzo [d] thiazole (500 mg, 1.46 mmol) in DCM (30 ml) m-CPBA (314 mg, 1.82 mmol) was added at 0 ° C. The reaction mixture was stirred for 2 h at 0 ° C, then aqueous Na2SO3 solution (15 ml) was added and the mixture was stirred for 0.5 h. The organic layer was separated, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with DCM / MeOH from 50: 1 to 20: 1 to give the 6 - ((6-methoxyimidazo [1,2b] pyridazin-3-yl) methyl) -2- ( Methylsulfinyl) benzo [d] thiazole in the form of a yellow solid (500 mg, 95%). 1H NMR (300 MHz, CDCl3) δ 7.99-7.93 (m, 2H), 7.76 (d, J = 9.6 Hz, 1H), 7.53 (dd, J = 1.5, 8.4 Hz, 1H), 7.46 (s, 1H), 6.65 (d, J = 9.3 Hz, 1H), 4.42 (s, 2H), 3.94 (s, 3H) , 3.06 (s, 3H). LCMS (ESI) m / z 359 (M + H) +.
Step 3: A mixture of 6 - ((6-methoxyimidazo [1,2-b] pyridazin-3-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole (320 mg, 0.89 mmol), ( 1R, 2R) -2-aminocyclohexanol (308 mg, 2.68 mmol) and DIEA (231 mg, 1.79 mmol) in NMP (11 ml) was stirred for 1 day at 140 ° C. The mixture was cooled to t.a. and water (50 ml) was added. The mixture was extracted with EtOAc (30 ml × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with DCM / MeOH from 50: 1 to 10: 1, then further purified by preparative HPLC to give (1R, 2R) -2 - ((6 - ((6- methoxyimidazo [1,2-b] pyridazin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol in the form of a brown solid (120 mg, 33%). 1H NMR (300 MHz, DMSO-d6) δ 7.97 (d, J = 9.6 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.61 (s, 1H ), 7.44 (s, 1H), 7.26 (d, J = 8.4 Hz, 1H), 7.18 (d, J = 9.9 Hz, 1H), 6.82 (d, J = 9.6 Hz, 1H), 4.72 (d, J = 5.4 Hz, 1H), 4.23 (s, 2H), 3.95 (s, 3H), 3.52-3.49 (m, 1H), 3.39-3.36 (m, 1H), 2.05-2.01 (m, 1H), 1.90-1.86 (m, 1H), 1.65-1 , 59 (m, 2H), 1.28-1.14 (m, 4H). LCMS (ESI) m / z 410 (M + H) +.
Example 151
Preparation of (1R, 2R) -2 - ((6 - ((5-methoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] oxazol-2-yl) amino) cyclohexanol
185
image186
image187
A2, 2008), and 2-chloro-3- (2- (methylthio) benzo [d] thiazol-6-yl) propanal used in example 117 by 2-chloro-3- (2 (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) propanal from step 2 of this example. 1H NMR (500 MHz, DMSO-d6) δ 8.00 (d, J = 7.4 Hz, 1H), 7.89 (d, J = 7.4 Hz, 1H), 7.49 (s, 1H ), 7.25 (d, J = 8.4 Hz, 1H), 7.23 (s, 1H), 7.06 (d, J = 7.9 Hz, 1H), 6.92 (d, J = 2.5 Hz, 1H), 6.58 (dd, J = 2.5, 7.4 Hz, 1H), 4.77 (d, J = 5.9 Hz, 1H), 4.22 (s , 2H), 4.07 4.16 (m, 2H), 3.60 -3.72 (m, 2H), 3.50 (wide s, 2H), 3.30 (s, 3H), 2, 04 (d, J = 12.3 Hz, 1H), 1.87 (d, J = 11.8 Hz, 1H), 1.53 -1.71 (m, 2H), 1.06 -1.36 (m, 4H). LCMS (ESI) m / z 453 (M + H) +.
Example 154
Preparation of (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) -5-fluorobenzo [d] thiazol-2-yl) amino) cyclohexanol
image188
Step 1: A mixture of 4-amino-2,5-difluorobenzonitrile (1.0 g, 6.5 mmol) and potassium salt of O-ethylxanthane acid (1.2 g, 7.8 mmol) in DMF (15 ml) was heated at reflux for 6 h. The mixture was cooled to t.a. and partitioned between EtOAc (200 ml) and 1 M aqueous Na2CO3 solution (100 ml). The organic layer was separated and the aqueous layer was extracted with additional EtOAc (2 × 200 ml). The combined organic layers were washed with brine (100 ml), dried over Mg2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash gel chromatography.
15 of silica eluting with MeOH in 2% DCM to give the potassium salt of 6-cyano-5-fluorobenzo [d] thiazol-2-thiolate (1.94 g) as an orange solid. LCMS (ESI) m / z 211 (M + H) +.
Stage 2: 5-Fluoro-2- (methylthio) benzo [d] thiazol-6-carbonitrile was synthesized in the form of an orange solid (1.2 g, 86%) using a procedure analogous to that described in step 2 of Example 114, replacing the potassium salt of ethyl 2-mercaptothiazolo [4,5-b] pyridine-6-carboxylate used in Example 114 with the potassium salt of 6-cyano-5
20 fluorobenzo [d] thiazol-2-thiolate from the previous stage. 1H NMR (300 MHz, DMSO-d6) δ 8.67 (d, J = 6.4 Hz, 1H), 8.01 (d, J = 10.5 Hz, 1H), 2.84 (s, 3H ); LCMS (ESI) m / z 225 (M + H) +.
Step 3: To a stirred mixture of 5-fluoro-2- (methylthio) benzo [d] thiazol-6-carbonitrile in anhydrous THF (20 ml) at -20 ° C under argon, lithium aluminum hydride was added dropwise (2M solution in THF, 11.7 ml, 5.9 mmol). After 1 h, water (500 µl) and 1 M NaOH aqueous solution (500 µl) were slowly added to the mixture of
25 reaction After 5 minutes, additional water (2 ml) was added and the mixture was stirred at t.a. for 30 minutes The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with 5% MeOH in CH2Cl2 to give the (5-fluoro-2- (methylthio) benzo [d] thiazol-6-yl) methanamine (128 mg, 29%) in form of a colorless oil. 1H NMR (500 MHz, DMSO-d6) δ 8.07 (d, J = 7.1 Hz, 1H), 7.64 (d, J = 11.1 Hz, 1H), 3.83 (s, 2H ), 2.78 (s, 3H), 1.80-2.06 (m, 2H); LCMS (ESI) m / z 229 (M + H) +.
Step 4: To a stirred mixture of (5-fluoro-2- (methylthio) benzo [d] thiazol-6-yl) methanamine (128 mg, 0.6 mmol) and DIEA (195 µl, 1.2 mmol) at 0 ° C under argon, 2-chloro-3-nitropyridine (98 mg, 0.7 mmol) was added in one portion. The mixture was stirred at t.a. for 18 h and then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel eluting with a gradient of 100% hexanes to 50% EtOAc in hexanes to give the N - ((5-fluoro-2- (methylthio) benzo [d] thiazol-6 -yl) methyl) -3-nitropyridin-2-amine (165 mg, 84%) as
35 of a yellow oil. LCMS (ESI) m / z 351 (M + H) +.
Step 5: N2 - ((5-Fluoro-2- (methylthio) benzo [d] thiazol-6-yl) methyl) pyridine-2,3-diamine was synthesized as a yellow solid (200 mg) using a analogous procedure to that described in step 2 of example 41, substituting the 4-bromo-5-methoxy-N - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -2-nitroaniline used in example 41 by the N - ((5-fluoro-2 (methylthio) benzo [d] thiazol-6-yl) methyl) -3-nitropyridin-2-amine of the previous step. LCMS (ESI) m / z 321 (M + H) +.
Step 6: The 6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) -5-fluoro-2- (methylthio) benzo [d] thiazole was synthesized as a brown solid clear (180 mg) using a procedure analogous to that described in step 3 of example 41, substituting 4-bromo-5-methoxy-N1 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) benzene- 1,2-diamine used in Example 41 by N2 - ((5fluoro-2- (methylthio) benzo [d] thiazol-6-yl) methyl) pyridine-2,3-diamine from the previous step. LCMS (ESI) m / z 331 (M + H) +.
Step 7: The 6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) -5-fluoro-2- (methylsulfinyl) benzo [d] thiazole was synthesized in the form of a
White foam (314 mg) using a procedure analogous to that described in step 6 of Example 36, substituting 6 - ((4-bromo-1 H -imidazol-1-yl) methyl) -2- (methylthio) benzo [d ] thiazole used in example 36 by the 6 - ((3H-imidazo [4,5b] pyridin-3-yl) methyl) -5-fluoro-2- (methylthio) benzo [d] thiazole of the previous step. LCMS (ESI) m / z 347 (M + H) +.
Stage 8: The (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) -5-fluorobenzo [d] thiazol-2-yl) amino ) Cyclohexanol was synthesized in the form of a white powder (42 mg, 19%) using a procedure analogous to that described in step 7 of Example 36, substituting 6 - ((4-bromo-1H-imidazol-1-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole used in example 36 by 6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) -5-fluoro-2- ( Methylsulfinyl) benzo [d] thiazole from the previous stage. 1H NMR (500 MHz, DMSO-d6) δ 8.50 (s, 1H), 8.36 (dd, J = 1.2, 4.7 Hz, 1H), 8.15 (d, J = 7, 6 Hz, 1H), 8.09 (dd, J = 1.1, 8.0 Hz, 1H),
188
image189
5
fifteen
25
35
Four. Five
Stage 2: To a solution of 6- (imidazo [2,1-b] thiazol-5-ylmethyl) -2- (methylthio) benzo [d] thiazole (350 mg, 1.1 mmol) in DCM (20 ml) m-CPBA (240 mg, 1.4 mmol) was added at 0 ° C. The reaction mixture was stirred for 2 h at 0 ° C, then aqueous Na2S2O3 solution (20 ml) was added and the mixture was stirred for 0.5 h. The organic layer was separated and dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with DCM / MeOH from 50: 1 to 20: 1 to give 6- (imidazo [2,1-b] thiazol-5-ylmethyl) -2 (methylsulfinyl) benzo [ d] thiazole in the form of a yellow solid (310 mg, 85%). 1H NMR (300 MHz, CDCl3) δ 8.00 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 0.9 Hz, 1H), 7.43 (dd, J = 1 , 5, 8.4 Hz, 1H), 7.18 (s, 1H), 7.03 (d, J = 4.5 Hz, 1H), 6.75 (dd, J = 0.9, 4, 5 Hz, 1H), 4.32 (s, 2H), 3.07 (s, 3H). LCMS (ESI) m / z 334 (M + H) +.
Stage 3: A mixture of 6- (imidazo [2,1-b] thiazol-5-ylmethyl) -2- (methylsulfinyl) benzo [d] thiazole (310 mg, 0.93 mmol), (1R, 2R) 2 -aminocyclohexanol (321 mg, 2.79 mmol) and DIEA (240 mg, 1.86 mmol) in NMP (10 ml) was stirred for 1 day at 130 ° C. The mixture was cooled to t.a. and water (50 ml) was added. The mixture was extracted with EtOAc (100 ml × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with DCM / MeOH from 50: 1 to 10: 1, and the product was further purified by preparative HPLC to give the (1R, 2R) -2 - ((6- (imidazo [2,1-b] thiazol-5-methylmethyl) benzo [d] thiazol-2-yl) amino) cyclohexanol in the form of a brown solid (100 mg, 28%). 1H NMR (300 MHz, DMSO-d6) δ 7.84 (d, J = 7.2 Hz, 1H), 7.68 (d, J = 4.5 Hz, 1H), 7.54 (d, J = 1.8 Hz, 1H), 7.27 (d, J = 8.1 Hz, 1H), 7.20 (dd, J = 0.9, 4.2 Hz, 1H), 7.10 (dd , J = 1. 8, 8.4 Hz, 1H), 7.02 (s, 1H), 4.71 (d, J = 4.8 Hz, 1H), 4.15 (s, 2H), 3 , 52-3.49 (m, 1H), 3.39-3.36 (m, 1H), 2.05-2.01 (m, 1H), 1.90-1.86 (m, 1H) , 1.65-1.59 (m, 2H), 1.30-1.16 (m, 4H). LCMS (ESI) m / z 385 (M + H) +.
Example 158
Preparation of (1R, 2R) -2 - ((6 - ((6-chloroimidazo [1,2-b] pyridazin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
image190
Stage 1: A mixture of 2-chloro-3- (2- (methylthio) benzo [d] thiazol-6-yl) propanal from step 4 of example 117 (1.5 g, 5.5 mmol) and 6- Chloropyridazin-3-amine (1.4 g, 11 mmol) in 1-butanol (60 ml) was heated at reflux overnight. Then the mixture was cooled to t.a. and water (120 ml) was added. The mixture was extracted with EtOAc (60 ml × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with DCM / MeOH from 50: 1 to 20: 1 to give 6 - ((6-chloroimidazo [1,2-b] pyridazin-3-yl) methyl) -2 - (methylthio) benzo [d] thiazole in the form of a yellow solid (1.6 g, 84%), 1 H NMR (300 MHz, CDCl 3) δ 7.89 (d, J = 9.6 Hz, 1 H), 7.81 (d, J = 8.4 Hz, 1H), 7.68 (dd, J = 0.6, 1.2 Hz, 1H), 7.53 (s, 1H), 7.37 (dd , J = 1.8, 8.4 Hz, 1H), 7.03 (d, J = 9.3 Hz, 1H), 4.40 (s, 2H), 2.78 (s, 3H). LCMS (ESI) m / z 347 (M + H) +.
Step 2: To a solution of 6 - ((6-chloroimidazo [1,2-b] pyridazin-3-yl) methyl) -2- (methylthio) benzo [d] thiazole (1.6 g, 4.6 mmol ) in DCM (90 ml) m-CPBA (1.0 g, 5.8 mmol) was added at 0 ° C. The reaction mixture was stirred for 2 h at 0 ° C, then aqueous Na2S2O solution was added; (45 ml) and the mixture was stirred for 0.5 h. The organic layer was separated, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with DCM / MeOH from 50: 1 to 20: 1 to give 6 - ((6-chloroimidazo [1,2-b] pyridazin-3-yl) methyl) -2 (Methylsulfinyl) benzo [d] thiazole in the form of a yellow solid (1.68 g, 100%). 1H NMR (300 MHz, CDCl3) δ 8.00 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 3.6 Hz, 1H), 7.89 (s, 1H), 7.58 (s, 1H), 7.53 (dd, J = 2.1, 8.7 Hz, 1H), 7.05 (d, J = 9.3 Hz, 1H), 4.48 (s , 2H), 3.07 (s, 3H). LCMS (ESI) m / z 363 (M + H) +.
Step 3: A mixture of 6 - ((6-chloroimidazo [1,2-b] pyridazin-3-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole (1.0 g, 2.7 mmol) , (1R, 2R) -2-aminocyclohexanol (0.93 g, 8.1 mmol) and DIEA (697 mg, 5.4 mmol) in NMP (40 ml) was stirred for 2 d at 140 ° C. The mixture was cooled to t.a. and water (150 ml) was added. The mixture was extracted with EtOAc (100 ml × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with DCM / MeOH from 50: 1 to 10: 1 to give (1R, 2R) -2 - ((6 - ((6-chloroimidazo [1,2-b] pyridazin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol as a brown solid (530 mg, 46%). 1H NMR (300 MHz, DMSO-d6) δ 8.20 (d, J = 9.6 Hz, 1H), 7.86 (d, J = 7.2 Hz, 1H), 7.63 (s, 1H ), 7.54 (d, J = 1.8 Hz, 1H), 7.32 (d, J = 9.9 Hz, 1H), 7.27 (d, J = 1.8 Hz, 1H), 7.12 (dd, J = 1.5, 8.4 Hz, 1H), 4.73 (d, J = 5.1 Hz, 1H), 4.29 (s, 2H), 3.52-3 , 49 (m, 1H), 3.39-3.36 (m, 1H), 2.05-2.01 (m, 1H), 1.90-1.86 (m, 1H), 1.65 -1.59 (m, 2H), 1.30-1.16 (m, 4H). LCMS (ESI) m / z 414 (M + H) +.
Example 159
Preparation of (1R, 2R) -2 - ((6 - ((6- (1H-pyrazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2 -il) amino) cyclohexanol
190
image191
image192
image193
image194
image195
image196
image197
image198
image199
image200
image201
image202
image203
image204
image205
image206
image207
image208
image209
Step 1: A mixture of 5-chloro-2-nitroaniline (6.0 g, 34.88 mmol) and NBS (6.06 g, 34.0 mmol) in HOAc (240 ml) was stirred at 130 ° C for 1 h . The reaction mixture was poured into water. The precipitate was collected by filtration and washed with petroleum ether to give 4-bromo-5-chloro-2-nitroaniline as a light brown solid (8.25 g, 96.5%). 1H NMR (300 MHz, DMSO-d6) δ 8.24 (s, 1H), 7.62 (wide s, 2H), 7.29 (s, 1H). LCMS (ESI) m / z 251 (M + H) +.
Step 2: To a solution of 4-bromo-5-chloro-2-nitroaniline (550 mg, 2.19 mmol) from the previous stage and TFA (2.26 ml) in DCM (10 ml) at -15 ° C was added NaBH (OAc) 3 (1.39 g, 5.37 mmol). Then a solution of 2- (methylthio) benzo [d] oxazol-6-carbaldehyde (465 mg, 2.41 mmol) in DCM (6 ml) was added to the mixture. After the addition was completed, the mixture was stirred from -10 ° C to 0 ° C for 2 h. The reaction mixture was diluted with DCM and washed sequentially with H2O, aqueous NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with petroleum ether / DCM from 5: 1 to 2: 1 to give 4-bromo-5-chloro-N - ((2- (methylthio) benzo [d] oxazole -6-yl) methyl) -2-nitroaniline in the form of a yellow solid (451 mg, 48.2%). 1H NMR (300 MHz, DMSO-d6) δ 8.81 (t, 1H), 8.34 (s, 1H), 7.66 (s, 1H), 7.60 (d, J = 8.1 Hz , 1H), 7.37 (d, J = 6.9 Hz, 1H), 7.19 (s, 1H), 4.76 (d, J = 6.3 Hz, 2H), 2.74 (s , 3H). LCMS (ESI) m / z 428 (M + H) +.
Step 3: To a stirred solution of 4-bromo-5-chloro-N - ((2- (methylthio) benzo [d] oxazol-6-yl) methyl) -2-nitroaniline (451 mg, 1.06 mmol) in methanol (80 ml) and DCM (80 ml) palladium on activated carbon (100 mg) was added. The mixture was stirred under a hydrogen atmosphere for 2 h, filtered and concentrated under reduced pressure to give 4-bromo-5-chloro-N1 ((2- (methylthio) benzo [d] oxazol-6-yl) methyl ) benzene-1,2-diamine in the form of a light yellow solid (415 mg, 98.6%). 1H NMR (300 MHz, DMSO-d6) δ 7.57-7.60 (m, 2H), 7.35 (d, J = 8.1 Hz, 1H), 6.81 (s, 1H), 6 , 41 (s, 1H), 5.64 (t, 1H), 5.03 (s, 2H), 4.40 (d, J = 6.0 Hz, 2H), 2.74 (s, 3H) . LCMS (ESI) m / z 399 (M + H) +.
Step 4: A mixture of 4-bromo-5-chloro-N1 - ((2- (methylthio) benzo [d] oxazol-6-yl) methyl) benzene-1,2-diamine (622 mg, 2.40 mmol ), triethoxymethane (5 ml) and HCOOH (0.08 ml) was stirred at 90 ° C for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was purified by chromatography on silica gel, eluting with petroleum ether / ethyl acetate 1: 1 to give 6 - ((5-bromo-6-chloro-1 H -benzo [d] imidazol-1-yl) methyl) -2 (methylthio) benzo [d] oxazole in the form of a light brown solid (607 mg, 84.5%). 1H NMR (300 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.07 (s, 1H), 8.02 (s, 1H), 7.72 (s, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.34 (d, J = 6.6 Hz, 1H), 5.60 (s, 2H), 2.73 (s, 3H). LCMS (ESI) m / z 408 (M + H) +.
Step 5: A solution of 6 - ((5-bromo-6-chloro-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylthio) benzo [d] oxazole (554 mg, 1.80 mmol) and m-CPBA (403 mg, 2.34 mmol) in DCM (18 ml) was stirred at 0 ° C for 3 h. The reaction mixture was washed with aqueous Na2S2O3 solution and brine. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by chromatography on silica gel eluting with petroleum ether / ethyl acetate 1: 5 to give 6 - ((5-bromo-6-chloro-1 H -benzo [d] imidazol-1-yl) methyl ) -2- (methylsulfinyl) benzo [d] oxazole (510 mg, 87.5%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 8.59 (s, 1H), 8.08 (s, 1H), 8.04 (s, 1H), 7.97 (s, 1H), 7.90 (d, J = 8.7 Hz, 1H), 7.50 (d, J = 9.3 Hz, 1H), 5.69 (s, 2H), 3.18 (s, 3H). LCMS (ESI) m / z 424 (M + H) +.
Step 6: A mixture of 6 - ((5-bromo-6-chloro-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylsulfinyl) benzo [d] oxazole (460 mg, 1.08 mmol), (1R, 2R) -2-aminocyclohexanol (245 mg, 2.13 mmol) and DIEA (366 mg, 2.84 mmol) in DMA (10 mL) was stirred at 120 ° C for 1 h. The reaction mixture was cooled to t.a., poured into water (30 ml) and extracted with ethyl acetate (100 ml × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with petroleum ether / ethyl acetate 1: 5 to give (1R, 2R) -2 - ((6 - ((5-bromo-6-chloro-1H-benzo) [d] imidazol-1il) methyl) benzo [d] oxazol-2-yl) amino) cyclohexanol as a light yellow solid (470 mg, 82.3%). 1H NMR (300 MHz, CDCl3) δ 8.52 (s, 1H), 8.06 (s, 1H), 8.00 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H ), 7.41 (s, 1H), 7.14 (s, 1H), 5.48 (s, 2H), 4.68 (d, J = 4.2 Hz, 1H), 3.33 (s wide, 2H), 1.91 (wide s, 2H), 1.63 (wide s, 2H), 1.25 (wide s, 4H). LCMS (ESI) m / z 477 (M + H) +.
Step 7: A mixture of (1R, 2R) -2 - ((6 - ((5-bromo-6-chloro-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] oxazol-2il) amino) cyclohexanol (215 mg, 0.45 mmol), Zn (CN) 2 (327 mg, 2.71 mmol), Pd2 (dba) 3 (82 mg, 0.09 mmol) and dppf (100 mg, 0, 18 mmol) in DMA (10 ml) was stirred at 100 ° C for 16 h. The reaction mixture was cooled to room temperature, poured into water (20 ml) and extracted with ethyl acetate (50 ml × 2). The combined organic layers were washed with water and brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC to give 6-chloro-1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] oxazol-6yl) methyl) -1H-benzo [d ] imidazol-5-carbonitrile in the form of a white solid (25 mg, 13.5%). 1H NMR (300 MHz, DMSOd6): δ 8.69 (s, 1H), 8.36 (s, 1H), 8.13 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.45 (s, 1H), 7.16 (s, 1H), 5.53 (s, 2H), 4.68 (d,
209
image210
image211
To a stirred solution of 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin7- il) ethanone (40 mg, 0.095 mmol) of example 200 in MeOH at rt NaBH4 was added. After 30 min, 3 N HCl was added and the mixture was purified by reverse phase HPLC using a mixture of water (5% CH3CN, 0.05% HCOOH) and CH3CN (0.05% HCOOH) as the Varian Pursuit XRs C18 mobile phase and column as the stationary phase 5 to give the (1R, 2R) -2 - ((6 - ((7- (1-hydroxyethyl) imidazo [1,2-a] pyridin-3-yl ) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol (23 mg, 58%) as a white powder. 1H NMR (500 MHz, DMSO-d6) δ 8.11 (d, J = 7.4 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.50 (s, 1H ), 7.41 (s, 1H), 7.37 (s, 1H), 7.26 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 7.9 Hz, 1H ), 6.84 (d, J = 7.4 Hz, 1H), 5.30 (wide s, 1H), 4.72 (q, J = 6.4 Hz, 2H), 4.26 (s, 2H), 3.50 (s wide, 1H), 2.03 (d, J = 11.8 Hz, 1H), 1.82 -1.87 (m, 1H), 1.55 -1.69 ( m, 2H), 1.32 (d, J = 6.9 Hz, 3H), 1.10-1.30 (m, 4H). LCMS (ESI)
10 m / z 423 (M + H) +.
Example 202
Preparation of the oxime of 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2a] pyridin-7 -il) ethanone
image212
15 To a stirred solution of 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin7 -il) ethanone (40 mg, 0.095 mmol) of example 200 in EtOH (2 ml) at rt hydroxylamine hydrochloride (120 mg, excess) and pyridine (200 µl, excess) were added. The mixture was heated at 90 ° C for 1 h, and then cooled to t.a. Purification by reverse phase HPLC using a mixture of water (5% CH3CN, 0.05% HCOOH), CH3CN (0.05% HCOOH) as the mobile phase and Varian Pursuit XRs C18 column as the stationary phase gave the oxime of
20 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7-yl ) ethanone (23 mg, 61%) in the form of a yellow powder. 1H NMR (500 MHz, DMSO-d6) δ 11.46 (broad s, 1H), 8.13 (d, J = 7.4 Hz, 1H), 7.90 (d, J = 7.4 Hz, 1H), 7.72 (s, 1H), 7.51 (s, 1H), 7.45 (s, 1H), 7.08 (d, J = 8.4 Hz, 1H), 6.44 - 6.58 (m, 1H), 5.89 (s, 1H), 4.78 (d, J = 2.5 Hz, 1H), 4.29 (s, 2H), 3.50 (wide s, 1H), 2.18 (s, 3H), 2.04 (d, J = 12.3 Hz, 1H), 1.87 (d, J = 10.8 Hz, 1H), 1.56 -1, 67 (m, 2H), 1.15 -1.32 (m, 4H). LCMS (ESI) m / z 436 (M + H) +.
25 Example 203
Preparation of (1R, 2R) -2 - ((6 - ((5-bromo-7-fluoro-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2yl) amino) cyclohexanol
image213
Step 1: A stirred mixture of acetic anhydride (20 ml, 213 mmol) and formic acid (8 ml, 213 mmol) was heated to
30 60 ° C for 3 h. The mixture was cooled to t.a. -bromo-2-fluoro-6-nitroaniline (2.5 g, 10.64 mmol) was added. The mixture was heated at 60 ° C for 15 h, cooled to t.a. and concentrated under reduced pressure. The residue was partitioned between saturated aqueous NaHO3 solution and DCM. The organic layer was separated, dried over MgSO4, filtered, and concentrated under reduced pressure to give N- (4-bromo-2-fluoro-6-nitrophenyl) formamide (2.79 g, 100%) as of a brown solid that was no longer purified. LCMS (ESI) m / z 285 and 287 (M + H + Na) +.
Step 2: A stirred solution of N- (4-bromo-2-fluoro-6-nitrophenyl) formamide (2.79 g, 10.61 mmol) of the previous stage in anhydrous DMF (40 ml) at 0 ° C is Sodium hydride (60% dispersion in mineral oil, 485 mg, 12.13 mmol) was added. The mixture was stirred at 0 ° C for 15 min, then allowed to warm to t.a. To the reaction mixture was added a solution of 6- (chloromethyl) -2- (methylthio) benzo [d] thiazole (3.04 g, 13.24 mmol) of step 3 of example 3 in DMF (10 ml) , and the mixture was stirred at rt for 15 h. The mixture was partitioned between water and DCM and the organic layer was
40 separated and washed sequentially with water and brine. The organic layer was separated, dried over MgSO4, filtered, and concentrated under reduced pressure to give N- (4-bromo-2-fluoro-6-nitrophenyl) -N - ((2- (methylthio) benzo [ d] thiazol-6il) methyl) formamide (4.8 g, 98%) in the form of an oil, which was no longer purified. LCMS (ESI) m / z 456 and 458 (M + H) +.
Step 3: To a stirred mixture of N- (4-bromo-2-fluoro-6-nitrophenyl) -N - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) formamide (4.8 g, 10.55 mmol) of the previous step, HOAc (15 ml) and EtOH (50 ml) at rt 45 powdered iron (1.77 g, 31.65 mmol) was added portionwise. The mixture was heated at 80 ° C for 2.5 h. After cooling to t.a., the mixture was partitioned between saturated aqueous NaHCO3 solution and a mixture of EtOAc and MeOH 10: 1. The biphasic mixture was filtered through Celite, and the layers of the filtrate were separated. The aqueous layer was extracted with a mixture of EtOAc and MeOH.
212
image214
image215
image216
image217
5
10
fifteen
twenty
25
30
35
(trifluoromethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazole in the form of a yellow solid (180 mg, 87.8%). 1H NMR (300 MHz, DMSO-d6) δ 8.91 (s, 1H), 8.77 (s, 1H), 8.59 (s, 1H), 8.23 (s, 1H), 8.08 (d, J = 8.1 Hz, 1H), 7.66-7.62 (m, 1H), 5.77 (s, 2H), 3.06 (s, 3H). LCMS (ESI) m / z 397 (M + H) +.
Step 5: A mixture of 2- (methylsulfinyl) -6 - ((6- (trifluoromethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazole (180 mg, 0 , 45 mmol), (1R, 2R) -2-aminocyclohexanol (112 mg, 0.97 mmol) and DIEA (261 mg, 2 mmol) in DMA (2 mL) was stirred at 130 ° C overnight. The reaction mixture was diluted with EtOAc and washed with brine. The organic layer was dried over NaSO4, filtered and concentrated under reduced pressure. The residue was purified by preparative HPLC to give the (1R, 2R) -2 - ((6 - ((6- (trifluoromethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [ d] thiazol-2-yl) amino) cyclohexanol in the form of a yellow solid (64 mg, 31.8%). 1H NMR (300 MHz, DMSO-d6) δ 8.84 (s, 1H), 8.78 (d, J = 1.2 Hz, 1H), 8.55 (d, J = 1.5 Hz, 1H ), 7.95 (d, J = 7. 8 Hz, 1H), 7.68 (d, J = 1.5 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 7.25-7.22 (m, 1H), 5.55 (s, 2H), 4.71 (d, J = 5.1 Hz, 1H), 3.52-3.50 (m, 1H) , 3.37-3.33 (m, 1H), 2.08-2.01 (m, 1H), 1.87-1.85 (m, 1H), 1.64-1.60 (m, 2H), 1.29-1.19 (m, 4H). LCMS (ESI) m / z 448 (M + H) +.
Example 213
Preparation of (1S, 2S) -2 - ((6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
image218
(1S, 2S) -2 - ((6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol it was synthesized in the form of a white powder (48 mg, 42%) using a procedure analogous to that described in step 5 of example 162, replacing the hydrochloride of (1S, 2R) -2-aminocyclohexanol used in example 162 with the ( 1S, 2S) -2aminocyclohexanol. 1H NMR (500 MHz, DMSO-d6) δ 8.67 (s, 1H), 8.41 (t, J = 2.0 Hz, 1H), 8.07 (dd, J = 2.6, 9, 5 Hz, 1H), 7.95 (d, J = 7.6 Hz, 1H), 7.66 (d, J = 1.2 Hz, 1H), 7.28 (m, 1H), 7.22 (dd, J = 1.5, 8.4 Hz, 1H), 5.48 (s, 2H), 4.72 (d, J = 5.2 Hz, 1H), 3.51 (m, 1H) , 3.33 (m, 1H), 2.02 (m, 1H), 1.87 (m, 1H), 1.57 -1.65 (m, 2H), 1.15 -1.29 (m , 4H); LCMS (ESI) m / z399 (M + H) +.
Example 214
Preparation of (1R, 2R) -2 - ((6 - ((7- (1H-imidazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2il ) amino) cyclohexanol
image219
(1R, 2R) -2 - ((6 - ((7- (1H-imidazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2- il) amino) cyclohexanol (27 mg, 47%) was obtained as a light brown solid using a procedure analogous to that described in example 141, substituting (1R, 2R) -2 - ((6 - ((6- iodine-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol and pyrazole used in example 141 by (1R, 2R) -2- ((6 - ((7-iodoimidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol of step 1 of example 167 and imidazole, respectively. 1H NMR (500 MHz, DMSO-d6) δ 8.42 (wide s, 1H), 8.34 (d, J = 6.9 Hz, 1H), 7.93 (wide s, 1H), 7.90 (d, J = 7.4 Hz, 2H), 7.54 (s, 1H), 7.49 (wide s, 1H), 7.33 (d, J = 7.4 Hz, 1H), 7, 27 (d, J = 8.4 Hz, 1H), 7.01 -7.19 (m, 2H), 4.77 (wide s, 1H), 4.33 (s, 2H), 3.51 ( s wide, 1H), 3.31 -3.34 (m, 2H), 2.04 (d, J = 11.8 Hz, 1H), 1.87 (d, J = 10.8 Hz, 1H) , 1.53 -1.70 (m, 2H), 1.06 -1.36 (m, 4H). LCMS (ESI) m / z 445 (M + H) +.
Example 215
Preparation of (1R, 2R) -2 - ((6 - ((7- (2H-1,2,3-triazol-2-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2il) amino) cyclohexanol
image220
217
The (1R, 2R) -2 - ((6 - ((7- (2H-1,2,3-triazol-2-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [ d] thiazol-2-yl) amino) cyclohexanol (13 mg, 23%) was obtained as a light brown solid using a procedure analogous to that described in example 141, replacing the (1R, 2R) -2 - (( 6 - ((6-iodo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol and pyrazole used in example 141 by (1R , 2R) -2 - ((6 - ((7-iodoimidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2
5 yl) amino) cyclohexanol from step 1 of example 167 and 1,2,3-triazole, respectively. 1H NMR (500 MHz, DMSO-d6) δ 8.40 (d, J = 7.4 Hz, 1H), 8.18 (s, 2H), 8.04 (s, 1H), 7.90 (d , J = 7.9 Hz, 1H), 7.63 (dd, J = 2.0, 7.4 Hz, 1H), 7.54 (s, 1H), 7.51 (s, 1H), 7 , 28 (d, J = 8.4 Hz, 1H), 7.11 (d, J = 6.9 Hz, 1H), 4.77 (wide s, 1H), 4.34 (s, 2H), 3.51 (wide s, 3H), 2.04 (d, J = 11.8 Hz, 1H), 1.87 (d, J = 11.3 Hz, 1H), 1.55 -1.69 ( m, 2H), 1.10 -1.36 (m, 4H). LCMS (ESI) m / z 446 (M + H) +.
10 Example 216
Preparation of (1R, 2R) -2 - ((6 - ((7-vinylimidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
image221
Step 1: The crude 4-vinylpyridin-2-amine (200 mg) was obtained in the form of a light brown solid using a procedure analogous to that described in example 98, substituting 4-iodopyridine-2-amine for (1R, 2R) -2 - ((6 - ((615 bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol used in example 98. LCMS (ESI) m / z 121 (M + H) +.
Stage 2: (1R, 2R) -2 - ((6 - ((7-vinylimidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol ( 13 mg, 8%) was obtained as a light brown solid using a procedure analogous to that described in step 6 of example 117, substituting 2-aminoisonicotinonitrile and 2-chloro-3- (2- (methylthio) benzo [d ] thiazol-6-yl) propanal used in Example 20 117 by the 4-vinylpyridin-2-amine of step 1 of this example and the 2-chloro-3- (2 - ((((1R, 2R) -2hydroxycyclohexyl ) amino) benzo [d] thiazol-6-yl) propanal of step 2 of example 153, respectively. 1H NMR (500 MHz, DMSO-d6) δ 8.14 (d, J = 6.9 Hz, 1H), 7.86 (d, J = 7.4 Hz, 1H), 7.52 (d, J = 3.4 Hz, 2H), 7.40 (s, 1H), 7.26 (d, J = 7.9 Hz, 1 H), 7.13 (d, J = 5.9 Hz, 1H) , 7.09 (d, J = 6.9 Hz, 1H), 6.77 (dd, J = 10. 8, 17.7 Hz, 1H), 5.91 (d, J = 17.7 Hz, 1H), 5.34 (d, J = 11.3 Hz, 1H), 4.72 (d, J = 3.4 Hz, 1H), 4.28 (s, 2H), 3.52 (d, J = 8.4 Hz, 2H), 2.03 (d, J = 10.8
25 Hz, 1H), 1.87 (d, J = 11.3 Hz, 1H), 1.54 -1.70 (m, 2H), 1.11 -1.36 (m, 4H). LCMS (ESI) m / z 405 (M + H) +.
Example 217
Preparation of (1R, 2R) -2 - ((6 - ((7- (allyloxy) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol
image222
Step 1: To a stirred solution of 2-aminopyridin-4-ol (500 mg, 4.5 mmol) in DMF (5 ml) at t.a. K2CO3 was added
30 (940 mg, 6.8 mmol). The resulting mixture was stirred at t.a. for 20 min before adding allyl bromide (393 µL, 4.5 mmol). The mixture was then stirred at t.a. overnight and heated at 60 ° C for 2 h. After cooling to t.a., the mixture was partitioned between EtOAc and water, and the organic layer was washed with brine, dried over Na2SO4, and evaporated under reduced pressure. The residue was purified by chromatography on silica gel eluting with EtOAc in hexanes to give 4- (allyloxy) pyridin-2-amine (110 mg, 16%) as a white solid. LCMS (ESI) m / z 151 (M + H) +.
35 Stage 2: The (1R, 2R) -2 - ((6 - ((7- (allyloxy) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol (56 mg, 34%) was obtained as a light brown solid using a procedure analogous to that described in step 6 of example 117, substituting 2-aminoisonicotinonitrile and 2-chloro-3- (2- (methylthio ) benzo [d] thiazol-6-yl) propanal used in example 117 by the 4- (allyloxy) pyridin-2-amine of step 1 of this example and 2-chloro-3- (2 - ((( 1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) propanal from step 2 of example 153, respectively. 1H NMR (500
40 MHz, DMSO-d6) δ 8.02 (d, J = 7.4 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.49 (s, 1H), 7 , 26 (d, J = 7.9 Hz, 1H), 7.23 (s, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.92 (d, J = 2, 5 Hz, 1H), 6.60 (dd, J = 2.5, 7.4 Hz, 1H), 5.96 -6.10 (m, 1H), 5.42 (d, J = 17.2 Hz, 1H), 5.28 (d, J = 10.3 Hz, 1H), 4.75 (s wide, 1H), 4.61 (d, J = 5.4 Hz, 2H), 4.22 (s, 2H), 3.51 (wide s, 2H), 2.04 (d, J = 11.8 Hz, 1H), 1.87 -1.94 (m, 1H), 1.55 -1 , 69 (m, 2H), 1.11 -1.36 (m, 4H). LCMS (ESI) m / z 435 (M + H) +.
Example 218
218
image223
image224
image225
image226
image227
image228
image229
5
10
fifteen
twenty
25
30
35
40
Four. Five
Stage 1: 4-Methoxy-N - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) -2-nitroaniline (5.2 g, 92%) was obtained as a red solid using a procedure analogous to that described in step 1 of example 127, substituting the 4-methyl-2-nitroaniline used in example 127 for 4-methoxy-2-nitroaniline. 1H NMR (500 MHz, DMSO-d6) δ 8.64 (t, J = 6.1 Hz, 1H), 7.98 (m, 1H), 7.80 (d, J = 8.4 Hz, 1H ), 7.52 (d, J = 3.1 Hz, 1H), 7.45 (dd, J = 8.4, 1.5 Hz, 1H), 7.18 (dd, J = 9.4, 3.1 Hz, 1H), 6.91 (d, J = 9.5 Hz, 1H), 4.72 (d, J = 6.1 Hz, 2H), 3.72 (s, 3H), 2 , 77 (s, 3H); LCMS (ESI) m / z 362 (M + H) +.
Stage 2: 4-Methoxy-N1 - ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) benzene-1,2-diamine (4 g, 84%) was obtained as an oil using a procedure analogous to that described in step 2 of example 129, substituting the 4-fluoro-N - ((2 (methylthio) benzo [d] thiazol-6-yl) methyl) -2-nitroaniline used in example 129 for the 4-methoxy-N - ((2- (methylthio) benzo [d] thiazol6-yl) methyl) -2-nitroaniline from the previous step. LCMS (ESI) m / z 332 (M + H) +.
Stage 3: The 6 - ((5-methoxy-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylthio) benzo [d] thiazole (1.12 g, 27%) was obtained as of a solid using a procedure analogous to that described in step 3 of example 129, substituting 4-fluoro-N1 ((2- (methylthio) benzo [d] thiazol-6-yl) methyl) benzene-1,2-diamine used in example 129 by the 4-methoxy-N1 - ((2 (methylthio) benzo [d] thiazol-6-yl) methyl) benzene-1,2-diamine of the previous step. 1H NMR (500 MHz, DMSO-d6) δ 8.35 (s, 1H), 7.97 (d, J = 1.2 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H ), 7.38-7.41 (m, 2H), 7.18 (d, J = 2.3 Hz, 1H), 6.82 (dd, J = 8.8, 2.3 Hz, 1H) , 5.55 (s, 2H), 3.75 (s, 3H), 2.76 (s, 3H); LCMS (ESI) m / z 342 (M + H) +.
Step 4: The 6 - ((5-methoxy-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole (986 mg, 84%) was obtained as a solid using a procedure analogous to that described in step 4 of example 129, substituting the 6 - ((5fluoro-1H-benzo [d] imidazol-1-yl) methyl) -2- (methylthio) benzo [d] thiazole used in Example 129 by the 6 - ((5-methoxy-1Hbenzo [d] imidazol-1-yl) methyl) -2- (methylthio) benzo [d] thiazole of the previous step. 1H NMR (500 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.21 (d, J = 1.2 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H ), 7.55 (dd, J = 8.5, 1.6 Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.19 (d, J = 2.3 Hz , 1H), 6.83 (dd, J = 8.8, 2.3 Hz, 1H), 5.64 (s, 2H), 3.75 (s, 3H), 3.05 (s, 3H) ; LCMS (ESI) m / z 358 (M + H) +.
Step 5: The (1R, 2S, 3R) -3 - ((6 - ((5-methoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) Cyclohexane-1,2-diol (53 mg, 15%) was obtained in the form of a solid using a procedure analogous to that described in step 5 of Example 232, replacing the 6 - ((5-iodo-1 H -benzo [d d] thiazole of Example 232 by 6 - ((5-methoxy-1 H -benzo [d] imidazol-1-yl) methyl) -2- (methylsulfinyl) benzo [d] thiazole, prepared as described in the previous step 1H NMR (500 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.62 (s, 1H), 7.40 ( d, J = 8.9 Hz, 1 H), 7.29 (d, J = 8.1 Hz, 1H), 7.13-7.20 (m, 2H), 6.82 (dd, J = 2.1, 8.7 Hz, 1H), 5.41 (s, 2H), 4.52 (d, J = 5.9 Hz, 1H), 4.43 (d, J = 3.7 Hz, 1H), 3.93 (d, J = 4.4 Hz, 1H), 3.79 (m, 1H), 3.75 (s, 3H), 3.40 (m, 1H), 1.91 ( dd, J = 3.8, 12.4 Hz, 1H), 1.51 -1.70 (m, 2H), 1.32 -1.45 (m, 2H), 1.20 (m, 1H) ; LCMS (ESI) m / z 425 (M + H) +.
Example 231
Preparation of (1R, 2S, 3R) -3 - ((6 - ((7- (2H-1,2,3-triazol-2-yl) imidazo [1,2-a] pyridin-3-yl) methyl ) benzo [d] thiazol-2il) amino) cyclohexane-1,2-diol
image230
Stage 1: 4- (2H-1,2,3-triazol-2-yl) pyridin-2-amine (370 mg, 39%) was obtained as a white solid using a procedure analogous to that described in the example 141, substituting (1R, 2R) -2 - ((6 - ((6-iodo-3H-imidazo [4,5-b] pyridin3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol and pyrazole used in example 141 by 4-iodopyridin-2-amine and 1,2,3-triazole, respectively. LCMS (ESI) m / z 162 (M + H) +.
Stage 2: The 6 - ((7- (2H-1,2,3-Triazol-2-yl) imidazo [1,2-a] pyridin-3-yl) methyl) -2- (methylthio) benzo [d ] thiazole (87 mg, 31%) was obtained in the form of a yellow solid using a procedure analogous to that described in step 6 of example 117, substituting the 2-aminoisonicotinonitrile used in example 117 for 4- (2H-1, 2,3-triazol-2-yl) pyridin-2-amine from step 1 of this example, and adding NaHCO3 to the reaction mixture. LCMS (ESI) m / z 379 (M + H) +.
Stage 3: The (1R, 2S, 3R) -3 - ((6 - ((7- (2H-1,2,3-Triazol-2-yl) imidazo [1,2-a] pyridin-3-yl ) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2-diol (35 mg, 33%) was obtained as a light brown solid using procedures 225
image231
image232
image233
image234
The compounds described herein were tested in an M-NFS-60 cell proliferation assay to determine their cellular potency against CSF1R. M-NFS-60 are mouse monocytic cells that depend on the binding of the M-CSF ligand to its receptor, CSF1R, to proliferate. Inhibition of CSF1R kinase activity will result in lower cell growth and / or death. This assay evaluates the potency of the compounds as CSF1R inhibitors by measuring the reduction of the Alamar blue reagent by viable cells.
On day one of the experiment, M-NFS-60 cells were maintained in RPMI complete medium (Omega Scientific) plus 10% FBS supplemented with 20 ng / ml M-CSF (R&D Systems). Flat bottom plates, treated with CT, of 96 wells were seeded with 10,000 cells / well with a volume of 100 µl per well. The cells were grown overnight at 37 ° C with 5% CO2.
On day two, the compounds were added to the cells in 9 different concentrations, with semi-logarithmic intervals together with a control reference compound that served as a positive control. The final concentration of DMSO was maintained at 5% for a final volume of 200 µl. The compounds were allowed to incubate with the cells for 72 hours at 37 ° C with 5% CO2.
On day five of the experiment, 40 µl of Alamar blue was added to each well and allowed to incubate for 3 hours. Alamar blue fluorescence was read using the SoftMax Pro program at 560 nm (excitation) and 590 nm (emission). IC50s were generated as an average of duplicates and represents the concentration of the test compound that achieves 50% inhibition of cell proliferation compared to the control.
In one embodiment, the compounds provided herein were found to have IC50 of about or less than about 5, 4, 3, 2, 1, 0.5, 0.1, 0.05 or 0.01 µM. In another embodiment, the compounds provided herein were found to have IC50 activity of about or less than about 2000, 1000, 500, 300, 100, 50, 40, 30 or 20 nM. In another embodiment, the compounds provided herein were found to have IC50 activity less than about 200 or 100 nM.
Example 238
CSF1R phosphorylation MSD assay of HEK293
The compounds described herein were tested in a CSF1R phosphorylation assay to determine their cellular potency against CSF1R. A HEK293 cell line was generated that expressed the CSF1R fused with the FK506 binding protein (FKBP) as a molecular marker. Inhibition of CSF1R kinase activity will prevent ligand-stimulated autophosphorylation of CSF1R-FKBP in intact cells. Subsequent cell lysates are assayed in a sandwich ELISA using Meso Scale Discovery (MSD) electrochemiluminescence technology to analyze the presence of phosphorylated (p) CSF1R-FKBP. This assay determines the potency of the compounds as CSF1R inhibitors by measuring the reduction in the amount of pCSF1R with increasing doses of the compounds added to the cells before stimulation of M-CSF.
On day one of the experiment, HEK293-CSF1R-FKPB cells maintained in DMEM, with L-glutamine (Mediatech), 10% FBS, and penicillin / streptomycin 100 units / ml, were seeded with 50,000 cells / well in a volume of 100 µl per well in 96-well plates Cell Bind (Costar). The cells were grown overnight at 37 ° C in 5% CO2. To prepare these plates used in the MSD assay, 30 µl per well of a 330 nM biotin-FK506 solution (in TBS pH 7.2) was added to streptavidin-coated 96-well (MSD) 96-well plates, and incubated for overnight at room temperature, stirring at 500 rpm on an orbital shaker.
On day two, compounds diluted in DMSO were added to the cells in duplicate plates in 9 different concentrations at semi-logarithmic intervals, plus control with only DMSO, together with a reference compound that served as a positive control. The final concentration in DMSO was 0.5% in a volume of 200 µl per well. The compounds were allowed to incubate with the cells for 2 h at 37 ° C with 5% CO2. At the end of the incubation, human M-CSF (R&D Systems) was added for 5 min with a final concentration of 50 ng / ml to stimulate phosphorylation of CSF1R. The cells were lysed for 20 min, and the lysates were applied to the FK506 coated MSD plates, washed, and incubated overnight at 4 ° C with shaking at 500 rpm.
On day three, the MSD plates were washed and analyzed in the CSF1R-FKBP sequentially captured phosphorylation using mouse anti-phosphotyrosine mouse antibody (Millipore) and goat anti-mouse IgG antibody labeled with Sulfo-TAG (MSD), and were detected in a Sector Imager 6000 (MSD) instrument.
A single IC50 value for each compound was determined by averaging the IC50 of the duplicates calculated using the Igor Pro 6 program, and represents the concentration of compound that achieves a 50% inhibition of ligand-induced CSF1R phosphorylation compared to the control of DMSO
Example 239
230
image235
Ex. Nº CSF1R Kd (nM)FLT3 Kd (nM)KIT Kd (nM)PDGFRβ Kd (nM)CSF1R M-NFS60 CTB: IC50 (nM)HEK293 pCSF1R M-CSF MSD: IC50 (nM)Specificity of Kinase S (10)
fifteen* CDCDDCND
16 CBBCDCND
17 * BBDBCCND
18 TOTOTOTOBTOND
19 * TOCBBBBND
twenty* CCDDDCND
twenty-one* DDDDDCND
22 * BCBDCBND
2. 3 TOTOTOBBTOND
24 * DDDDDDND
25 * DDDDDDND
26 * BBDDDDND
27 * BCBBBBND
28 * BTOTOTOBBND
29 BBTOBBTOND
30 * TOCTOBBBND
31 * TOCBBDDND
32 * DBDDDDND
33 BBTOTOBBC
3. 4 BTOBBBBC
35 TOTOTOTOBTOC
36 * BDCDBBTO
37 * DDDDDDTO
38 CDCDCCTO
39 TOTOTOTOTOTOC
40 TOTOTOTOTOTOB
41 BBBCBBTO
42 * TOCTOTOBBB
43 BCBBBBB
44 BDCCBBTO
Four. Five TOBTOTOTOTOB
46 * TOCBTOBBB
47 BBTOBTOBB
48 * BDCBBBTO
49 * BCCCBCTO
fifty* TOTOTOTOTOTOC
51 TOTOTOTOTOTOC
52 TOTOTOBBTOC
53 BCBBTOTOB
54 CDBBBBTO
232 233
Ex. Nº CSF1R Kd (nM)FLT3 Kd (nM)KIT Kd (nM)PDGFRβ Kd (nM)CSF1R M-NFS60 CTB: IC50 (nM)HEK293 pCSF1R M-CSF MSD: IC50 (nM)Specificity of Kinase S (10)
55 BCTOTOTOTOB
56 BBTOTOBBC
57 * TOBTOTOBBC
58 TOCTOTOBBB
59 BCBBBBC
60 BCBTOBBB
61 BTOTOTOTOTOC
62 * TOBTOTOTOTOC
63 BTOTOTOBBC
64 BBTOTOBCC
65 BCCDBBB
66 BDCBCBTO
67 BCTOBBBB
68 BCBBTOTOTO
69 * TOCBTOBBND
70 TOCTOBBTOND
71 * BDDCCCND
72 * BDDCCBND
73 BCBTOBTOTO
74 BTOBBBBB
75 BCTOTOBBC
76 TOTOTOTOBBC
77 * BCCCCBTO
78 BTOTOTOTOTOND
79 BBTOTOTOTOND
80 * BBTOTOTOTOB
81 CCBBDDB
82 BCCBCCTO
83 * TOTOCBBBTO
84 BCBBBTOTO
85 TOBTOTOTOTOB
86 BBTOTOBTOC
87 TOBTOTOTOTOB
88 TOBTOBTOBND
89 BCTOTOBBND
90 BCBBBBND
91 DTOBBBDND
92 BCTOTOBBND
93 BBTOTODDND
94 BBBBTOTOND
Ex. Nº CSF1R Kd (nM)FLT3 Kd (nM)KIT Kd (nM)PDGFRβ Kd (nM)CSF1R M-NFS60 CTB: IC50 (nM)HEK293 pCSF1R M-CSF MSD: IC50 (nM)Specificity of Kinase S (10)
95 * TODCTOBBND
96 BTOTOTOTOTOC
97 BBTOTOTOTOB
98 BBTOTOTOTOB
99 DCDCDCTO
100 BCBBBBTO
101 * CBCBBBB
102 BBTOTOTOTOB
103 * BDDBBBND
* Comparative examples In Table 1, CSF1R Kd (nM): A ≤5, 5 <B≤20, 20 <C≤50, D> 50; and ND = no data; FLT3 Kd (nM): A ≤200, 200 <B≤1000, 1000 <C≤5000, D> 5000; and ND = no data;
5 KIT Kd (nM): A ≤100, 100 <B≤500, 500 <C≤2000, D> 2000; and ND = no data; PDGFRβ Kd (nM): A ≤50, 50 <B≤500, 500 <C≤2000, D> 2000; and ND = no data; CSF1R cell proliferation assay (M-NSF-60) IC50 (nM): A ≤50, 50 <B≤400, 400 <C≤1500, D> 1500; and ND = no data; PCSF1R test in HEK293 (M-CSF MSD) IC50 (nM): A ≤50, 50 <B≤200, 200 <C≤500, D> 500; and ND = there is no
10 data; and S Score: A ≤0.01, 0.01 <B≤0.02, C> 0.02; and ND = no data.
It was found that additional compounds provided herein had the following activity shown in Table 2:
Table 2
Ex. Nº CSF1R Kd (nM)FLT3 Kd (nM)KIT Kd (nM)PDGFRβ Kd (nM)CSF1R M-NFS-60 CTB: IC50 (nM)HEK293 pCSF1R M-CSF MSD: IC50 (nM)Specificity of Kinase S (10)
104 TOTOTOTOTOTOTO
105 * BBCCCCTO
106 CBCCDDTO
107 BCBBBBB
108 BDCCBBTO
109 CCBBBBTO
110 TOCBBBTOTO
111 BCCCBBTO
112 CCCCDCTO
113 CCCDDCTO
114 DCBCDBTO
115 DCCBBBTO
116 BBBBDBND
117 BDDBCDTO
118 * CCBQCDTO
119 BBTOTOBBTO
120 BCBBBBB
121 BCBBBBTO
122 BBBBBBTO
234 235 236
Ex. Nº CSF1R Kd (nM)FLT3 Kd (nM)KIT Kd (nM)PDGFRβ Kd (nM)CSF1R M-NFS-60 CTB: IC50 (nM)HEK293 pCSF1R M-CSF MSD: IC50 (nM)Specificity of Kinase S (10)
123 BBTOTOBBB
124 BBTOTOBBB
125 * BCCBCBB
126 BBBBBTOTO
127 BCBTOBBTO
128 BDBBCCB
129 TOCTOTOBTOB
130 BCBTOBCTO
131 TOTOTOTOTOTOB
132 TOTOTOTOBBC
133 BCBTOBBTO
134 BBBTOBTOTO
135 BDCCBBND
136 BCTOTOBBB
137 TOBTOTOTOTOTO
138 TOBTOTOTOTOTO
139 CBBBCCTO
140 BDCBCCTO
141 TOBTOTOTOTOB
142 TOTOTOTOBTOC
143 BCCCCCB
144 TOBBBBBB
145 TOCBTOBTOTO
146 BBTOTOBTOB
147 TOBTOTOBTOTO
148 TOCTOBBBTO
149 BCBTOBCTO
150 TOBTOBBBB
151 BBTOTOBTOB
152 BTOTOBBTOB
153 BCCBBTOTO
154 BCCCBBTO
155 TOTOTOBBTOB
156 BCDCCCTO
157 * CDDCCDTO
158 TOBTOTOTOTOB
159 BCCCCCTO
160 TOBTOTOTOTOTO
161 BCBBBTOTO
162 TOCBBBBTO
Ex. Nº CSF1R Kd (nM)FLT3 Kd (nM)KIT Kd (nM)PDGFRβ Kd (nM)CSF1R M-NFS-60 CTB: IC50 (nM)HEK293 pCSF1R M-CSF MSD: IC50 (nM)Specificity of Kinase S (10)
163 DDBBDDTO
164 BCDCCDTO
165 BDCCCDTO
166 BBCDCDTO
167 TOCBBTOTOTO
168 BCDDCDTO
169 BCCBBBTO
170 DDDCDDTO
171 BBTOTOBTOC
172 TOBBBBTOB
173 BBBBBBB
174 TOTOTOTOTOTOB
175 BBBBBBTO
176 * BCBBCCB
177 TOTOTOTOTOTOC
178 BBCCCCB
179 BCTOTOCCB
180 CCBBDDTO
181 BCBTOCCB
182 TOBBBBTOTO
183 TOBTOBTOTOB
184 BBTOBBCTO
185 BTOTOTOBBB
186 BTOBBCCB
187 BDDCCBTO
188 BCDCCBTO
189 BBCCBCTO
190 CBCCBDTO
191 * CCBCDDTO
192 BCBTOCCB
193 BCTOTOTOTOTO
194 BBTOTOBBB
195 CCCCCCTO
196 TOBBBBTOTO
197 * BDBBCDTO
198 TOCBTOBCB
199 BDDDDCTO
200 BDCBBBTO
201 CCCCDCTO
202 BCBBBBTO
Ex. Nº CSF1R Kd (nM)FLT3 Kd (nM)KIT Kd (nM)PDGFRβ Kd (nM)CSF1R M-NFS-60 CTB: IC50 (nM)HEK293 pCSF1R M-CSF MSD: IC50 (nM)Specificity of Kinase S (10)
203 BBTOBBBTO
204 BCBBBBTO
205 * BBCBCDB
206 BBBBBBTO
207 BTOTOTOTOBB
208 TOTOTOTOTOBB
209 BBBBBBTO
210 CDCCDCTO
211 TOTOTOTOTOTOC
212 BBTOTOBBTO
213 TOBTOTOBBB
214 TODBBBTOB
215 BCCCBBTO
216 BCCBBBTO
217 BCCBBBTO
218 BCCBBTOTO
219 BCBTOCBB
220 * CDDBDDTO
221 TOTOTOTOTOTOB
222 * CDDCDDTO
223 BCBBBBTO
224 BBTOBDDTO
225 TOBTOTOCBND
226 TOBTOTOTOTOB
227 BCBBTOTOB
228 DDCBDDTO
229 BBTOTOBTOTO
230 BBTOTOTOTOTO
231 BCCBTOTOTO
232 TOTOTOTOTOTOTO
233 TOBTOTOBTOTO
2. 3. 4 BBTOTOBBTO
235 BBTOTOBBTO
236 BBBBBBTO
* Comparative examples In Table 2, CSF1R Kd (nM): A ≤5, 5 <B≤20, 20 <C≤50, D> 50; and ND = no data; FLT3 Kd (nM): A ≤200, 200 <B≤1000, 1000 <C≤5000, D> 5000; and ND = no data; KIT Kd (nM): A ≤100, 100 <B≤500, 500 <C≤2000, D> 2000; and ND = no data;
237
image236
image237

权利要求:
Claims (14)
[1]
image 1
image2
image3
image4
image5
image6
1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -5-methoxy-1H-benzo [d] imidazol-6-carbonitrile, 1 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -5-methoxy-1 H -benzo [d] imidazol-6-carbonitrile, (R) -2 - (( 6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanone, 2 - ((6 - ((3H-imidazo [4, 5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanone, (1R, 2R) -2 - ((6 - ((6-chloro-3H-imidazo [4, 5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6-chloro-3H-imidazo [4,5-b] pyridin-) 3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl)) methyl) benzo [d] oxazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] oxazol-2- il) amino) cyclohexanol oxime of (R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino ) Cyclohexanone oxime of 2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanone, (1S, 2R ) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin) -3-yl) methyl) benzo [d] thiazol-2-yl) amino) -1-methylcyclohexanol, (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridine) 3-yl) methyl) benzo [d] thiazol-2-yl) amino) -1-methylcyclohexanol, 2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -1-methylcyclohexanol, (1R, 2R) -2 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl)) methyl) benzo [d] oxazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6-bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] oxazol-2-yl) amino) cyclohexanol, (S) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -2-cyclohexyletanol, 2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -2-cyclohexyletanol, (R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) -2-cyclohexylethanol, 1- ( (2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -6-methoxy-1H-benzo [d] imidazol-5-carbonitrile, 1 - (( 2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -6-methoxy-1 H -benzo [d] imidazol-5-carbonitrile, ((1R, 2R) -2 - (( 6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) be nzo [d] thiazol-2-yl) amino) cyclohexyl) methanol, 2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2- il) amino) cyclohexyl) methanol, (1R, 2R) -2 - ((6 - ((6-methoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6-methoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) - 2 - ((6 - ((5-methoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((5- methoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6-fluoro-3H- imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6-fluoro-3H-imidazo [4,5- b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d ] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridin-6-yl) ethanone, 1- (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazole -6-yl) methyl) -3H-imidazo [4,5-b] pyridin-6-yl) ethanone, (1R, 2R) -2 - ((6 - ((6- (methylsulfonyl) -3H-imidazo [ 4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6- (methylsulfonyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 1 - (((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) methyl) cyclohexanol, (1 - (((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) methyl) cyclohexyl) methanol, (1R, 2R) -2 - ((6 - ((5-Bromo-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((5-bromo -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl ) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] methyl pyridine-6-carboxylate, 3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [ d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] methyl pyridine-6-carboxylate, 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino)) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-6-carboxylic acid, 3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazole- 6-yl) methyl) -3H-imidazo [4,5-b] pyridine-6-carboxylic acid, (1R, 2R) -2 - ((6 - ((6- (morpholinomethyl) -3H -imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6- (morpholinomethyl) -3H-imidazo [4 , 5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6- (hydroxymethyl) -3H-imidazo) [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6- (hydroxymethyl) -3H-imidazo [4,5] -b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6- (methylthio) -3H-imidazo [4 , 5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6- (methylthio) -3H-imidazo [4,5-b ] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6 - ((methylthio) methyl) -3H-imidazo [ 4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6 - (((methylthio) methyl)) -3H-imidazo [4 , 5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d ] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridine-5-carbonitrile, 3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridi na-5-carbonitrile, 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5- b] pyridin-5-yl) ethanone, 1- (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridin-5-yl) ethanone, 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -N-methyl-3H-imidazo [4 , 5-b] pyridine-6-carboxamide, 3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -N-methyl-3H-imidazo [4,5- b] pyridine-6-carboxamide, N-hydroxy-3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4 , 5-b] pyridine-6
carboximidamide,
acetic acid salt of (1R, 2R) -2 - ((6 - ((6- (aminomethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2il ) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6- (aminomethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2 -yl) amino) cyclohexanol, 2 - ((6 - ((6- (aminomethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino ) cyclohexanol, 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -N, N-dimethyl-3H-imidazo [4,5- b] pyridine-6
carboxamide, 3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -N, N-dimethyl-3H-imidazo [4,5-b] pyridine-6-carboxamide , (1R, 2R) -2 - ((6 - ((6- (2H-tetrazol-5-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazole -2-yl) amino) cyclohexanol, 2 - ((6 - ((6- (2H-tetrazol-5-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d ] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6- (2-methyl-2H-tetrazol-5-yl) -3H-imidazo [4,5-b ] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6- (2-methyl-2H-tetrazol-5-yl) -3H-imidazo) [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6- (1-methyl- 1H-tetrazol-5-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6 - - (1-methyl-1H-tetrazol-5-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6-ethynyl-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2- ( (6 - ((6-ethynyl-3 H -imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohe xanol, (1R, 2R) -2 - ((6 - ((6-morpholino-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6-morpholino-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R ) -2 - ((6 - ((6-vinyl-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - (( 6 - ((6-vinyl-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, N - ((3 - ((2- ( (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridin-6-yl) methyl) acetamide, N- ( (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridin-6-yl) methyl) acetamide, (1R , 2R) -2 - ((6 - ((5-bromo-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6- ((5-Bromo-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, (1R, 2R) -2 - ((6 - ((6- ethyl-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol, 2 - ((6 - ((6-ethyl-3H-imidazo [ 4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane l, (1R, 2R) -2 - ((6 - ((6- (3-hydroxy-3-methylbut-1-in-1-yl) -3H-imidazo [4,5-b] pyridin-3- il) methyl) benzo [d] thiazol-2
il) amino) cyclohexanol; 2 - ((6 - ((6- (3-hydroxy-3-methylbut-1-in-1-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((5- (methylsulfonyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((5- (methylsulfonyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((6-bromo-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((6-Bromo-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1H-benzo [d] imidazol-5-carbonitrile; 1 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1 H -benzo [d] imidazol-5-carbonitrile; (1R, 2R) -2 - ((6 - ((6- (2-hydroxypropan-2-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol- 2-yl) amino) cyclohexanol; 2 - ((6 - ((6- (2-hydroxypropan-2-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 1- (1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1H-benzo [d] imidazol-5-yl) ethanone; 1- (1 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1 H -benzo [d] imidazol-5-yl) ethanone; 1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1 H -benzo [d] imidazol-6-carbonitrile; 1 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1 H -benzo [d] imidazol-6-carbonitrile; (1R, 2R) -2 - ((6 - ((5- (methylsulfonyl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((5- (methylsulfonyl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((6- (methylsulfonyl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((6- (methylsulfonyl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) thiazolo [4,5-b] pyridin-2-yl) amino) cyclohexanol; 2 - ((6 - ((3 H -imidazo [4,5-b] pyridin-3-yl) methyl) thiazolo [4,5-b] pyridin-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((6 - ((R, S) -1-hydroxyethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((6- (1-hydroxyethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2- (dimethylamino) -1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H acetate salt
imidazo [4,5-b] pyridin-6-yl) ethanone; 2- (dimethylamino) -1- (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5-b] pyridin-6- il) ethanone; 2- (dimethylamino) -1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -3H-imidazo [4,5- b] pyridin-6
il) ethanone; 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridine-7-carbonitrile; 3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridine-7-carbonitrile; (1R, 2R) -2 - ((6 - ((5,6-dimethyl-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((5,6-dimethyl-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol;
image7
image8
image9
image10
N- (2-Chlorocyclohexyl) -6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-amine; 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7-yl) piperidin -4-ol; 1- (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7-yl) piperidin-4-ol; 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7-yl) ethanone ; 1- (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7-yl) ethanone; (1R, 2R) -2 - ((6 - ((7- (1-hydroxyethyl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol ; 2 - ((6 - ((7- (1-hydroxyethyl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; oxime of 1- (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7- il) ethanone; 1- (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7-yl) ethanone oxime; (1R, 2R) -2 - ((6 - ((5-bromo-7-fluoro-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((5-Bromo-7-fluoro-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 1- (3 - ((2 - ((((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridine-) 7
il) ethanone; 1- (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7-yl) ethanone O-methyl oxime; 7-fluoro-1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1H-benzo [d] imidazol-5-carbonitrile; 7-fluoro-1 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1 H -benzo [d] imidazol-5-carbonitrile; (1R, 2R) -2 - ((6 - ((7-fluoro-5-vinyl-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((7-fluoro-5-vinyl-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((5- (3,6-dihydro-2H-pyran-4-yl) -7-fluoro-1H-benzo [d] imidazol-1-yl) methyl)) benzo [d] thiazol-2
il) amino) cyclohexanol; 2 - ((6 - ((5- (3,6-dihydro-2 H -pyran-4-yl) -7-fluoro-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazole- 2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((5-morpholino-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((5-morpholino-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 1- (1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1H-benzo [d] imidazol-5-yl) piperidine- 2-one; 1- (1 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1 H -benzo [d] imidazol-5-yl) piperidin-2-one; (1R, 2R) -2 - ((6 - ((5- (1H-pyrazol-3-yl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((5- (1 H -pyrazol-3-yl) -1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((6- (trifluoromethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((6- (trifluoromethyl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1S, 2S) -2 - ((6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((7- (1H-imidazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl ) amino) cyclohexanol; 2 - ((6 - ((7- (1 H -imidazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((7- (2H-1,2,3-triazol-2-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d ] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((7- (2H-1,2,3-triazol-2-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl ) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((7-vinylimidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((7-vinylimidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol;
(1R, 2R) -2 - ((6 - ((7- (allyloxy) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((7- (allyloxy) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((7- (1H-1,2,3-triazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d ] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((7- (1H-1,2,3-triazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl ) amino) cyclohexanol; N - ((1R, 2S) -2-Chlorocyclohexyl) -6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-amine; N- (2-Chlorocyclohexyl) -6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-amine; 3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-b] pyridazine-6-carbonitrile; 3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-b] pyridazine-6-carbonitrile; (3 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [[1,2-a] pyridin-7-yl) (pyrrolidin -1-yl) methanone; (3 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) imidazo [1,2-a] pyridin-7-yl) (pyrrolidin-1-yl) methanone; (E) -3- (1 - ((2 - (((1R, 2R) -2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1H-benzo [d] imidazol-5 -il) acrylic; (E) -3- (1 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1 H -benzo [d] imidazol-5-yl) acrylic; 3- (1 - ((2 - ((2-hydroxycyclohexyl) amino) benzo [d] thiazol-6-yl) methyl) -1 H -benzo [d] imidazol-5-yl) acrylic acid; (1R, 2R) -2 - ((6 - ((5- (1,2,3,6-tetrahydropyridin-4-yl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((5- (1,2,3,6-tetrahydropyridin-4-yl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((5- (1H-imidazol-1-yl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; 2 - ((6 - ((5- (1 H -imidazol-1-yl) -1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1R, 2R) -2 - ((6 - ((5- (2-methyl-2H-tetrazol-5-yl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol- 2-yl) amino) cyclohexanol; 2 - ((6 - ((5- (2-methyl-2H-tetrazol-5-yl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol; (1S, 2R, 3R) -3 - ((6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2-diol; 3 - ((6 - ((6-fluoro-3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2-diol; (1R, 2S, 3R) -3 - ((6 - ((7- (1H-pyrazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2 -yl) amino) cyclohexane-1,2-diol; 3 - ((6 - ((7- (1 H -pyrazol-1-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1 , 2-diol; (1R, 2S, 3R) -3 - ((6 - ((5-methoxy-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1, 2-diol; 3 - ((6 - ((5-methoxy-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2-diol; (1R, 2S, 3R) -3 - ((6 - ((7- (2H-1,2,3-triazol-2-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2
diol; 3 - ((6 - ((7- (2H-1,2,3-triazol-2-yl) imidazo [1,2-a] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl ) amino) cyclohexane-1,2-diol; (1R, 2S, 3R) -3 - ((6 - ((5-vinyl-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1, 2-diol; 3 - ((6 - ((5-vinyl-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2-diol; (1R, 2S, 3R) -3 - ((6 - ((5- (oxetan-3-yloxy) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2-diol; 3 - ((6 - ((5- (oxetan-3-yloxy) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2- diol; (1R, 2S, 3R) -3 - ((6 - ((6- (1H-1,2,4-triazol-1-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane
1,2-diol; 3 - ((6 - ((6- (1H-1,2,4-triazol-1-yl) -3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazole- 2-yl) amino) cyclohexane-1,2-diol; (1R, 2S, 3R) -3 - ((6 - ((5-morpholino-1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1, 2-diol; 3 - ((6 - ((5-morpholino-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2-diol;
(1R, 2S, 3R) -3 - ((6 - ((5- (2-methyl-2H-tetrazol-5-yl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane 1,2-diol; Y
3 - ((6 - ((5- (2-methyl-2H-tetrazol-5-yl) -1H-benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexane-1,2-diol.
[13]
13. The compound of claim 1 which is (1R, 2R) -2 - ((6 - ((3H-imidazo [4,5-b] pyridin-3-yl) methyl) benzo [d] thiazol2-yl) amino)) cyclohexanol or a pharmaceutically acceptable salt thereof.
[14]
14. The compound of claim 1 which is N-cyclohexyl-6 - ((5,6-dimethoxy-1 H -benzo [d] imidazol-1-yl) methyl) benzo [d] thiazol-2-amine or a pharmaceutically acceptable salt thereof .
[15]
fifteen. The compound of claim 1 which is (1R, 2R) -2 - ((6 - ((5-methoxy-3H-imidazo [4,5-b] pyridin-3yl) methyl) benzo [d] thiazol-2- il) amino) cyclohexanol or a pharmaceutically acceptable salt thereof.
[16]
16. The compound of claim 1 which is (1R, 2R) -2 - ((6 - ((5-methoxy-1H-benzo [d] imidazol-1yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol or a pharmaceutically acceptable salt thereof.
[17]
17. The compound of claim 1 which is (1R, 2R) -2 - ((6 - ((5,6-dimethoxy-1H-benzo [d] imidazol-1yl) methyl) benzo [d] thiazol-2-yl) amino) cyclohexanol or a pharmaceutically acceptable salt thereof.
[18]
18. The compound of one of claims 13-17, wherein the pharmaceutically acceptable salt is a mineral acid salt.
[19]
19. A pharmaceutical composition comprising a compound of any one of claims 118 and a pharmaceutically acceptable carrier.
[20]
twenty. The compound of any one of claims 1-18 for use in a method for the treatment of a disease selected from an inflammatory disease, an inflammatory condition, an autoimmune disease and cancer, wherein the method comprises administering a therapeutically effective amount of the compound. .
[21]
twenty-one. The compound for use of claim 20, wherein the disease is modulated by CSF1R, FLT3, KIT and / or PDGFRβ kinase.
[22]
22 The compound for use of claim 20, wherein the disease is modulated by CSF1R, FLT3, KIT and / or PDGFRβ kinase of the wild type or mutant.
[23]
2. 3. The compound of any one of claims 1-18, for use in a method for the treatment of a disease, wherein the method comprises administering a therapeutically effective amount of the compound, and wherein the disease is selected from myeloproliferative disorder (MPD). , myelodysplastic syndrome (SMD), polycythemia vera (PCV), essential thrombocytopenia (TE), primary myelofibrosis (MFP), chronic eosinophilic leukemia (LEC), chronic myelomonocytic leukemia (LMMC), systemic mastocytosis (MS), idiopathic myelofibrosis (MFI) , myeloid leukemia, chronic myeloid leukemia (CML), imitamib-resistant CML, acute myeloid leukemia (AML), acute megakaryoblastic leukemia (AML), lymphoma, Hodgkin lymphoma, lymphoblastic leukemia, myeloma, multiple myeloma, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, endometrial cancer, melanoma, lung cancer, brain cancer, thyroid cancer, stomach cancer, tumor r of the gastrointestinal stroma, colorectal cancer, pancreatic cancer, renal cancer, non-small cell lung cancer, bone cancer, giant cell tenosynovial tumors, glioblastoma multiforme, atherosclerosis, restenosis, bronchiolitis obliterans, idiopathic myelofibrosis, obesity, resistance to Obesity-induced insulin, malignant tumor hypercalcemia, lupus nephritis, glomerular nephritis, idiopathic hypereosinophilic syndrome, chronic eosinophilic syndrome, systemic mastocytosis, Langerhans cell histiocytosis, Kaposi's sarcoma, multiple endocrine neoplasia, immunodeficiency, autoimmune transplant diseases of tissues, graft versus host disease, wound, kidney disease, multiple sclerosis, thyroiditis, type 1 diabetes, sarcoidosis, psoriasis, allergic rhinitis, inflammatory bowel disease including Crohn's disease and ulcerative colitis (UC), systemic lupus erythematosus (SLE), cutaneous lupus erythematosus, arthritis, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, osteoporosis, endometriosis, asthma, allergic asthma, ankylosing spondylitis, chronic obstructive pulmonary disease (COPD), Alzheimer's disease and multiple sclerosis
[24]
24. The compound for use of claim 22, further comprising administering a second pharmaceutical agent selected from antiproliferative agent, anti-inflammatory agent, immunomodulatory agent and immunosuppressive agent.
[25]
25. The compound of any one of claims 1-18, for use in a method of modulating a CSF1R, FLT3, KIT and / or PDGFRβ kinase.

类似技术:

---

公开号 | 公开日 | 专利标题

---

ES2586527T9|2017-06-19|Heterocyclic compounds and use thereof as type III tyrosine kinase receptor modulators

---

KR101862493B1|2018-05-29|Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

---

ES2364901T3|2011-09-16|PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N4-FENIL-QUINAZOLIN-4-AMINA.

---

ES2886587T3|2021-12-20|Heterocyclic compounds as RET kinase inhibitors

---

IL267458D0|2019-08-29|Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1l internalization inducers

---

DK2651939T3|2015-06-01|Substituted N- | imidazo [1,2-a] pyridine-3-carboxamide as Type-III-RECEPTOR-tyrosine kinase inhibitors

---

ES2312783T3|2009-03-01|DERIVATIVES OF 1H-IMIDAZO | QUINOLINA FOR THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE.

---

JP6510068B2|2019-05-08|Novel biphenyl compound or salt thereof

---

US9365566B2|2016-06-14|Cinnoline derivatives

---

ES2527222T3|2015-01-21|Azabicyclo compound and salt thereof

---

JP2012528828A5|2014-07-03|

---

MX2015004151A|2015-07-06|Gdf-8 inhibitors.

---

MX2014014110A|2015-06-17|Pteridines as fgfr inhibitors.

---

AU2012284540B2|2014-08-28|TRPV4 antagonists

---

CA2763821A1|2010-12-09|1h-imidazo[4,5-c]quinolinone derivatives

---

AU2007296441A1|2008-03-20|Kinase inhibitors useful for the treatment of proliferative diseases

---

CA2705405A1|2009-05-28|New compounds

---

JP6549311B2|2019-07-24|Indole derivatives, process for their preparation and their use in medicine

---

CA2942997A1|2015-09-24|Heteroaryl syk inhibitors

---

KR20160132114A|2016-11-16|TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

---

AU2005295091A1|2006-04-20|Substituted biaryl quinolin-4-ylamine analogues

---

WO2013117645A1|2013-08-15|Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases

---

JP2017503834A|2017-02-02|Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory diseases

---

WO2018078360A1|2018-05-03|Modulators of hedgehog | signalling pathway

---

JP2013512952A|2013-04-18|Heterocyclic compounds containing indole cores

同族专利:

---

公开号 | 公开日

---

HRP20160744T2|2017-08-11|

---

PH12015501955A1|2018-03-19|

---

IN2014CN03597A|2015-10-09|

---

JP6162130B2|2017-07-12|

---

KR20140075010A|2014-06-18|

---

WO2013056070A2|2013-04-18|

---

JP2014528482A|2014-10-27|

---

KR102066297B1|2020-01-14|

---

MX2014004252A|2014-06-11|

---

TW201811777A|2018-04-01|

---

TWI650321B|2019-02-11|

---

CA2851155C|2021-02-23|

---

TWI605043B|2017-11-11|

---

BR112014009006A2|2017-04-18|

---

HUE027745T4|2017-09-28|

---

HK1200814A1|2015-08-14|

---

CA2851155A1|2013-04-18|

---

RU2014119244A|2015-11-20|

---

EP2766359A2|2014-08-20|

---

MX368081B|2019-09-19|

---

ZA201402549B|2015-08-26|

---

PH12014500794B1|2014-10-20|

---

RU2648997C2|2018-03-29|

---

US20150196566A1|2015-07-16|

---

HUE027745T2|2016-10-28|

---

RS54936B1|2016-11-30|

---

US8952058B2|2015-02-10|

---

EP2766359B9|2017-04-05|

---

US9452167B2|2016-09-27|

---

WO2013056070A3|2013-08-01|

---

CN104066730B|2017-03-08|

---

MY167575A|2018-09-20|

---

NZ623274A|2016-05-27|

---

HRP20160744T1|2016-09-23|

---

AR089568A1|2014-09-03|

---

US9938261B2|2018-04-10|

---

US20160362405A1|2016-12-15|

---

ES2586527T3|2016-10-17|

---

EP2766359B1|2016-04-13|

---

US20130096113A1|2013-04-18|

---

PL2766359T3|2016-11-30|

---

DK2766359T3|2016-07-25|

---

IL231927A|2017-01-31|

---

CY1117745T1|2017-05-17|

---

AU2012322095B2|2017-06-29|

---

SMT201600223B|2016-08-31|

---

IL231927D0|2014-05-28|

---

PH12015501955B1|2018-03-19|

---

SI2766359T1|2016-09-30|

---

SG11201401236XA|2014-05-29|

---

AU2012322095A1|2014-04-17|

---

CN104066730A|2014-09-24|

---

TW201321376A|2013-06-01|

---

PT2766359T|2016-07-14|

---

DK2766359T5|2017-06-26|

---

PH12014500794A1|2014-10-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3536809A|1969-02-17|1970-10-27|Alza Corp|Medication method|

---

US3598123A|1969-04-01|1971-08-10|Alza Corp|Bandage for administering drugs|

---

US3845770A|1972-06-05|1974-11-05|Alza Corp|Osmatic dispensing device for releasing beneficial agent|

---

US3916899A|1973-04-25|1975-11-04|Alza Corp|Osmotic dispensing device with maximum and minimum sizes for the passageway|

---

US4008719A|1976-02-02|1977-02-22|Alza Corporation|Osmotic system having laminar arrangement for programming delivery of active agent|

---

US4104385A|1976-08-19|1978-08-01|Sterling Drug Inc.|Cyclic alkylidenyl N-[6--3-pyridazinyl]aminomethylenemalonates|

---

KR890002631B1|1984-10-04|1989-07-21|몬산토 캄파니|Composition of prolonged release of biologically active somatotropin|

---

IE58110B1|1984-10-30|1993-07-14|Elan Corp Plc|Controlled release powder and process for its preparation|

---

US5073543A|1988-07-21|1991-12-17|G. D. Searle & Co.|Controlled release formulations of trophic factors in ganglioside-lipsome vehicle|

---

IT1229203B|1989-03-22|1991-07-25|Bioresearch Spa|USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.|

---

PH30995A|1989-07-07|1997-12-23|Novartis Inc|Sustained release formulations of water soluble peptides.|

---

US5120548A|1989-11-07|1992-06-09|Merck & Co., Inc.|Swelling modulated polymeric drug delivery device|

---

US5585112A|1989-12-22|1996-12-17|Imarx Pharmaceutical Corp.|Method of preparing gas and gaseous precursor-filled microspheres|

---

IT1246382B|1990-04-17|1994-11-18|Eurand Int|METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON|

---

US5733566A|1990-05-15|1998-03-31|Alkermes Controlled Therapeutics Inc. Ii|Controlled release of antiparasitic agents in animals|

---

US5543390A|1990-11-01|1996-08-06|State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University|Covalent microparticle-drug conjugates for biological targeting|

---

US5580578A|1992-01-27|1996-12-03|Euro-Celtique, S.A.|Controlled release formulations coated with aqueous dispersions of acrylic polymers|

---

FR2687932B1|1992-02-27|1994-08-19|Oreal|

---

TW333456B|1992-12-07|1998-06-11|Takeda Pharm Ind Co Ltd|A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.|

---

US5591767A|1993-01-25|1997-01-07|Pharmetrix Corporation|Liquid reservoir transdermal patch for the administration of ketorolac|

---

US6274552B1|1993-03-18|2001-08-14|Cytimmune Sciences, Inc.|Composition and method for delivery of biologically-active factors|

---

US5523092A|1993-04-14|1996-06-04|Emory University|Device for local drug delivery and methods for using the same|

---

US5985307A|1993-04-14|1999-11-16|Emory University|Device and method for non-occlusive localized drug delivery|

---

US6087324A|1993-06-24|2000-07-11|Takeda Chemical Industries, Ltd.|Sustained-release preparation|

---

US6004534A|1993-07-23|1999-12-21|Massachusetts Institute Of Technology|Targeted polymerized liposomes for improved drug delivery|

---

IT1270594B|1994-07-07|1997-05-07|Recordati Chem Pharm|CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN|

---

US5759542A|1994-08-05|1998-06-02|New England Deaconess Hospital Corporation|Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases|

---

US5660854A|1994-11-28|1997-08-26|Haynes; Duncan H|Drug releasing surgical implant or dressing material|

---

US6316652B1|1995-06-06|2001-11-13|Kosta Steliou|Drug mitochondrial targeting agents|

---

AU6242096A|1995-06-27|1997-01-30|Takeda Chemical Industries Ltd.|Method of producing sustained-release preparation|

---

TW448055B|1995-09-04|2001-08-01|Takeda Chemical Industries Ltd|Method of production of sustained-release preparation|

---

US6419961B1|1996-08-29|2002-07-16|Takeda Chemical Industries, Ltd.|Sustained release microcapsules of a bioactive substance and a biodegradable polymer|

---

JP2909418B2|1995-09-18|1999-06-23|株式会社資生堂|Delayed release microsphere of drug|

---

US6039975A|1995-10-17|2000-03-21|Hoffman-La Roche Inc.|Colon targeted delivery system|

---

US5980945A|1996-01-16|1999-11-09|Societe De Conseils De Recherches Et D'applications Scientifique S.A.|Sustained release drug formulations|

---

TW345603B|1996-05-29|1998-11-21|Gmundner Fertigteile Gmbh|A noise control device for tracks|

---

US6264970B1|1996-06-26|2001-07-24|Takeda Chemical Industries, Ltd.|Sustained-release preparation|

---

NZ334914A|1996-10-01|2000-09-29|Stanford Res Inst Int|Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique|

---

CA2217134A1|1996-10-09|1998-04-09|Sumitomo Pharmaceuticals Co., Ltd.|Sustained release formulation|

---

DE69730093T2|1996-10-31|2006-07-20|Takeda Pharmaceutical Co. Ltd.|Preparation with delayed release|

---

ZA9711385B|1996-12-20|1999-06-18|Takeda Chemical Industries Ltd|Method of producing a sustained-release preparation|

---

US5891474A|1997-01-29|1999-04-06|Poli Industria Chimica, S.P.A.|Time-specific controlled release dosage formulations and method of preparing same|

---

US6120751A|1997-03-21|2000-09-19|Imarx Pharmaceutical Corp.|Charged lipids and uses for the same|

---

US6060082A|1997-04-18|2000-05-09|Massachusetts Institute Of Technology|Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery|

---

DE69833224T2|1997-11-10|2006-09-28|Bristol-Myers Squibb Co.|BENZOTHIAZOLE AS PROTEIN TYROSINE KINASE INHIBITORS|

---

NZ505651A|1998-01-16|2003-08-29|Takeda Chemical Industries Ltd|Sustained release composition comprising biologically active substance, hydroxynaphthoic acid and biodegradable polymer|

---

US6613358B2|1998-03-18|2003-09-02|Theodore W. Randolph|Sustained-release composition including amorphous polymer|

---

US6048736A|1998-04-29|2000-04-11|Kosak; Kenneth M.|Cyclodextrin polymers for carrying and releasing drugs|

---

KR19990085365A|1998-05-16|1999-12-06|허영섭|Biodegradable polymer microspheres capable of continuously controlled controlled release and preparation method thereof|

---

US6131570A|1998-06-30|2000-10-17|Aradigm Corporation|Temperature controlling device for aerosol drug delivery|

---

US6271359B1|1999-04-14|2001-08-07|Musc Foundation For Research Development|Tissue-specific and pathogen-specific toxic agents and ribozymes|

---

US6248363B1|1999-11-23|2001-06-19|Lipocine, Inc.|Solid carriers for improved delivery of active ingredients in pharmaceutical compositions|

---

PL357099A1|2000-02-07|2004-07-12|Abbott Gmbh & Co.Kg|2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors|

---

DK1392306T3|2001-06-06|2008-05-19|Aventis Pharma Ltd|Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases|

---

WO2003087089A1|2002-04-16|2003-10-23|Teijin Limited|Piperidine derivatives having ccr3 antagonism|

---

US7112435B1|2002-08-07|2006-09-26|Ambit Biosciences Corporation|Uncoupling of DNA insert propagation and expression of protein for phage display|

---

FR2851563B1|2003-02-26|2005-04-22|Sod Conseils Rech Applic|NOVEL BENZIMIDAZOLE AND IMIDAZO-PYRIDINE DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT|

---

NZ542304A|2003-03-14|2009-07-31|Ono Pharmaceutical Co|Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient|

---

US7531553B2|2003-03-21|2009-05-12|Amgen Inc.|Heterocyclic compounds and methods of use|

---

DE10349587A1|2003-10-24|2005-05-25|Merck Patent Gmbh|Benzimidazolylderivate|

---

EP1679309A4|2003-10-24|2007-03-28|Ono Pharmaceutical Co|Antistress drug and medical use thereof|

---

AR046959A1|2003-12-18|2006-01-04|Tibotec Pharm Ltd|MORFOLINILO CONTAINING BENCIMIDAZOLS AS INHIBITORS OF THE REPLICATION OF RESPIRATORY SYNTHETIC VIRUSES|

---

AU2004298459B2|2003-12-18|2011-03-17|Tibotec Pharmaceuticals Ltd.|5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication|

---

US7470712B2|2004-01-21|2008-12-30|Bristol-Myers Squibb Company|Amino-benzazoles as P2Y1 receptor inhibitors|

---

WO2005100373A2|2004-04-13|2005-10-27|Ranbaxy Laboratories Limited|Monosaccharide derivatives as anti-cancer and anti-inflammatory agents|

---

US6969498B1|2004-05-07|2005-11-29|Riley Medical, Inc.|Surgical instrument bracket assembly|

---

JP2006070014A|2004-08-04|2006-03-16|Hisamitsu Medical Kk|2-aminobenzothiazole derivative|

---

WO2006136561A1|2005-06-20|2006-12-28|Tibotec Pharmaceuticals Ltd|1- -3h-benzimidazoiylmethyl) -3-subtituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus|

---

US20080146536A1|2005-08-16|2008-06-19|Pharmacopeia, Inc.|2-Aminoimidazopyridines for treating neurodegenerative diseases|

---

JP4610668B2|2006-03-17|2011-01-12|アムビトビオスシエンセスコルポラチオン|Imidazolothiazole compounds for treating diseases|

---

KR101280333B1|2006-03-28|2013-07-02|하이 포인트 파마슈티칼스, 엘엘씨|Benzothiazoles having histamine ｈ３ receptor activity|

---

EP2405272B1|2006-06-30|2015-01-14|DiscoveRx Corporation|Detectable nucleic acid tag|

---

CN101679422A|2007-03-28|2010-03-24|阵列生物制药公司|Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors|

---

EP2152700B1|2007-05-21|2013-12-11|Novartis AG|Csf-1r inhibitors, compositions, and methods of use|

---

WO2009050228A2|2007-10-18|2009-04-23|Novartis Ag|Csf-1r inhibitors for treatment of cancer and bone diseases|

---

US8153813B2|2007-12-20|2012-04-10|Abbott Laboratories|Benzothiazole and benzooxazole derivatives and methods of use|

---

US8309577B2|2008-04-23|2012-11-13|Bristol-Myers Squibb Company|Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands|

---

US7863291B2|2008-04-23|2011-01-04|Bristol-Myers Squibb Company|Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands|

---

ES2647317T3|2008-11-03|2017-12-20|Syntarga B.V.|Analogs of CC-1065 and its conjugates|

---

UY32470A|2009-03-05|2010-10-29|Boehringer Ingelheim Int|DERIVATIVES OF 2- {2-CHLORINE-5 - [ METHYL] PHENYLAMINE} -1-METHYL] PHENYLAMINE} -1-METHYLBENCIMIDAZOL-5-CARBOXAMIDES-N- AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS, COMPOSITIONS AND APPLIANCE|

---

CN102985420B|2010-06-01|2017-07-04|安吉翁生物医药有限公司|Cytochrome P 450 inhibitors and application thereof|

---

KR20130108543A|2010-08-05|2013-10-04|암젠 인코포레이션|Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase|

---

EP2655334B1|2010-12-22|2018-10-03|Eutropics Pharmaceuticals, Inc.|Compositions and methods useful for treating diseases|EP2906040B1|2012-08-22|2021-02-17|Merck Sharp & Dohme Corp.|Novel benzimidazole tetrahydropyran derivatives|

---

AR097543A1|2013-09-06|2016-03-23|Lexicon Pharmaceuticals Inc|COMPOUNDS BASED ON IMIDAZO [1,2-b] PIRIDAZINE, COMPOSITIONS THAT INCLUDE THEM AND THEIR METHODS OF USE|

---

US20190263799A1|2015-12-14|2019-08-29|Zenith Epigenetics Ltd.|1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors|

---

CA3019950A1|2016-04-04|2017-10-12|Massachusetts Institute Of Technology|Compositions of crystallized hydrophobic compounds and methods of making and using same|

---

EP3493853A1|2016-08-03|2019-06-12|Pfizer Inc|Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates|

---

MX2019004822A|2016-11-14|2019-09-11|Jiangsu Hengrui Medicine Co|3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof.|

---

EP3570836A4|2017-01-23|2020-08-19|The University of Hawaii|2-arylsulfonamido-n-arylacetamide derivatized stat3 inhibitors|

---

JP2021505600A|2017-12-07|2021-02-18|ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン|NSD family inhibitors and methods of treatment with them|

---

EP3833762A1|2018-08-09|2021-06-16|Verseau Therapeutics, Inc.|Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof|

---

WO2021047677A1|2019-09-12|2021-03-18|中国科学院上海药物研究所|Irak4 kinase inhibitor and preparation thereof and use thereof|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

US201161547637P| true| 2011-10-14|2011-10-14|

---

US201161547637P|2011-10-14|

---

US201261638990P| true| 2012-04-26|2012-04-26|

---

US201261638990P|2012-04-26|

---

PCT/US2012/059983|WO2013056070A2|2011-10-14|2012-10-12|Heterocyclic compounds and methods of use thereof|

---